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ABSTRACT 
Background: Biological sex can impact the pathogenesis and outcome of viral infection by 
modulating immune responses that control inflammation, antibody production, and tissue repair. 
Influenza B viruses (IBVs) are classified into B/Yamagata and B/Victoria lineages, which co-
circulate during the influenza season with varying dominance. Epidemiological data show 
greater circulation and diseases caused by IBV in recent years, with higher hospitalization and 
mortality rate in males than females, especially in children and the elderly. Compared with 
influenza A viruses (IAVs), however, studies of IBV are still lacking.  
Methods: We developed a mouse model to study the sex differences in the pathogenesis of IBV 
infection. Adult male and female C57BL/6 mice were intranasally infected with 105 TCID50 units 
of the B/Brisbane/60/2008 (Victoria lineage), carrying the PB2 F406Y mutation that increases 
virulence in mice. Morbidity and mortality were monitored for 15 days. Lungs were harvested 
and homogenized at 1, 3, 5, and 7 days post infection (dpi) to characterize viral kinetics. Lungs, 
spleens and sera were collected at 3 and 7 dpi for cytokine quantification to analyze the innate 
immune response. Neutralizing antibody titers were also determined in sera collected at 21 dpi. 
Results: Male mice experienced greater morbidity, i.e., had greater body mass loss and 
hypothermia, than females. Biological sex affected lung viral kinetics, in which males 
consistently had higher virus titers than females. Males showed aberrant innate responses in the 
lungs, with lower local induction of cytokines than females in the lungs at 3 dpi, but sustained 
inflammation at 7 dpi of IBV infection. Both males and females showed peripheral induction of 
cytokines in the spleen and sera at 3 dpi and to a stronger extent at 7dpi, with no sex differences 
observed. Neutralizing antibody titers were significantly lower in males than females at 21 dpi.  
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Conclusion: Taken together, these data suggest that males experience more severe disease than 
females following IBV infection. Impaired viral clearance combined with compromised innate 
and adaptive immune responses in males compared with females may contribute to worse IBV 
outcomes. The effects of biological sex on IBV pathogenesis and responses to vaccines should 
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INTRODUCTION 
Overview of Influenza Viruses 
Influenza viruses, including influenza A, B, C and D viruses, are in the Orthomyxoviridae 
family (Table 1). Respectively, they are the only species in Alphainfluenzavirus, 
Betainfluenzavirus, Gammainfluenzavirus and Deltainfluenzavirus genera. Influenza A Virus 
(IAV) has a variety of hosts, including avian, swine, and human. In contrast, humans are the only 
known host of Influenza B Virus (IBV). It has been reported sporadically that IBV can infect 
seals, but there is still no evidence of the transmission from seals to humans [1-4]. Despite the 
limited host range, IBV can cause severe disease that is comparable to IAV, which makes IBV a 
public health concern. Influenza C Virus (ICV) was first isolated from human throat washings in 
1947 and classified as a new type of influenza by Francis et al in 1950 [5-7]. Serological studies 
showed that the antibodies to ICV were prevalent in adults, indicating possible childhood ICV 
infections [5, 8-10]. However, compared to IAV and IBV, ICV only induces mild symptoms, and 
is not a significant pathogen of seasonal influenza. Influenza D Virus (IDV) is a recently 
identified influenza virus, which mainly infects swine and cattle. In 2013, when IDV was first 
discovered, it was recognized as a novel strain of ICV [11]. Subsequently, IDV was 
characterized as a new species in the Orthomyxoviridae family in 2014[12]. To date, there are no 
reports of human-related IDV infection.  
Influenza viruses are enveloped viruses with segmented, single stranded, negative sense 
RNA genome, which code for different functional proteins. Single-stranded RNAs (ssRNAs) are 
covered by Nucleocapsid Proteins (NP). The viral polymerase (P) subunits, PA, PB1 and PB2, 
are attached to the ribonucleoprotein (RNP) and essential for virus replication. IAV and IBV 
have 8 segments in the genome, while ICV and IDV have 7 segments (Table 1). These segments 
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are enveloped by the matrix protein (M1) covered with a lipid bilayer from the infected host cell, 
with glycoproteins protruding on the surface. The virions of IAV and IBV are indistinguishable 
under electron microscope, which are usually in spherical or filament shapes and have two types 
of glycoproteins, including hemagglutinin (HA) and neuraminidase (NA), on the surface, which 
are the major surface antigens of influenza virus. In IAV, M2 proteins lay on the matrix, whereas 
in IBV BM2 and NB proteins are the matrix proteins. Distinct from IAV and IBV, the virions of 
ICV and IDV are more pleomorphic. Filamentous structures are more common in ICV and IDV 
and they can form long cordlike structures on the surface of infected cells. Beyond that, the 
surface glycoproteins on ICV and IDV are organized in a hexagonal pattern and are only consist 
of hemagglutinin-esterase-fusion (HEF) proteins. Similar to IAV, there are CM2 proteins 
overlaying the matrix (Table 1). 
The influenza viruses can be further divided according to the genetic and antigenic 
differences. In IAV, 18 subtypes of HA (H1 to H18) and 11 subtypes of NA (N1 to N11) have 
been identified. And IAVs are divided into a variety of subtypes based on their HA and NA 
subtypes, for example, H1N1 and H7N9. In contrast, IBVs are only divided into two lineages, 
namely Yamagata and Victoria, by the sequence and antigenicity of HA [13]. ICV and IDV, 
which have HEF, instead of HA and NA, as the surface antigenic proteins, are further typed into 
lineages according to HEF. At present, there are six known lineages of ICV and four known 
lineages of IDV [14, 15]. 
The genomes of all influenza viruses are segmented ssRNAs. RNA virus polymerase 
lacks the activity of proofreading, resulting in an error-prone replication[16]. Therefore, HA 
proteins are of great variance with a high mutation rate. Under the immune pressure from the 
host immune response, these mutations can be selected and accumulated, leading to minor 
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changes on the antigen, termed antigenic drift. The variance of antigen can also be developed by 
reassortment, termed antigenic shift, which takes advantage of the segmented genome. When 
two different strains of influenza virus infect a same cell simultaneously, their genome segments 
can mix up and form a new strain with distinct characteristics. Antigenic shift frequently occurs 
in IAV, because IAV has been adapted to aquatic avian, which serves as a gene pool for IAV 
evolution. Antigenic shift of IAV usually induces influenza outbreaks. IBV also undergoes 
antigenic drifts and antigenic shifts. Evidence shows that antigenic shifts are of more importance 
in the evolution of IBV[17, 18]. However, the evolution rate is much slower than IAV because 
with limited animal reservoir, IBV lacks non-human gene pool [18, 19]. Within a type of 
influenza, the reassortment can occur within a lineage or between lineages[20]. Intertypical 
reassortment between influenza viruses has not been reported, which can be attributed to the 
incompatible packaging signals in different types of influenza virus [21]. 
Only IAV and IBV induce severe diseases in humans and are of epidemiologic interest.  
Historically, there have been four influenza pandemics: 1918 H1N1, 1957 H2N2, 1968 H3N2, 
and 2009 H1N1; all were caused by IAV substrains [22]. The pandemic is partially attributed to 
the fast evolution rate of IAV. The antigenic shifts lead to significant change in the surface 
antigens (HA and/or NA). Because humans are immunologically naïve to the new antigen, the 
novel IAV strain can readily infect and replicate in the host cells, often with greater 
transmissibility and virulence than seasonal strains, contributing to defining these as pandemic 
strains. The pandemic IAV strain will continue to circulate worldwide, undergoing antigenic 
drift, and eventually becoming a seasonal strain of IAV [23, 24]. IBV, which has limited hosts 
and thereby lower evolution rate, is not known to cause pandemics, while it co-circulates with 
IAV to cause seasonal influenza and can induce severe disease, similar to IAV. The receptors of 
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the two lineages of IBV are different (Table 2). Victoria lineage viruses recognize the Sialyl α-
2,3 Galactose as well as the Sialyl α-2,6 Galactose, while Yamagata lineage viruses only 
recognize the Sialyl α-2,6 Galactose. The difference in receptor binding may partially explain the 
epidemiological differences present between the two lineages. Generally, younger people are 
more susceptible to Victoria lineage viruses, with peak cases in individuals below 10 years of 
age.  In contrast, the age distribution of disease caused by Yamagata lineage viruses peak among 
individuals younger than 10 years of age and again among middle-aged adults [25, 26]. Victoria 
lineage induces more severe disease and greater hospitalization rates than Yamagata lineage 
viruses [27]. Compared with Yamagata lineage viruses, the transmission of Victoria lineage 
viruses is more sustained within a region [26]. The circulating IAVs and IBVs, influenza-
associated hospitalizations and mortalities are under continuous surveillance by the Centers of 
Disease Control and Prevention (CDC) in the United States as well as in other countries. 
Seasonal influenza is a substantial health burden in humans. As is estimated by World Health 
Organization (WHO), each year globally, seasonal influenza results in 3-5 millions of severe 
cases and 290 000-650 000 deaths due to respiratory diseases[28]. Aside from IAV, which is 
drawing a lot of attention, IBV is causing greater circulation and diseases in recent years[25, 29]. 
In 2019-20 season, 61.7% of pediatric mortality was caused by IBV[30]. Therefore, it is of great 
value and indispensable to have comprehensive understanding of IAV and IBV to control the 
influenza transmission and infection more efficiently. 
The Life Cycle of Influenza A Viruses 
After invading into host organism, the HA of IAVs bind to the sialyl-galactose residues 
on the surface of host cells, primarily respiratory epithelial cells. Sialic acid linked to either the 
3’ carbon or 6’ carbon of the galactose can be recognized by influenza HA, namely Sialyl α-2,3 
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Gal and Sialyl α-2,6 Gal. Sialyl α-2,3 Gal is regard as the avian receptor and Sialyl α-2,6 Gal is 
regard as the human receptor of influenza viruses, as avian influenza viruses preferentially bind 
the Sialyl α-2,3 Gal and human influenza viruses preferentially bind the Sialyl α-2,6 Gal [31, 
32]. Sialyl α-2,3 Gal is found in the avian intestinal epithelial cells, where avian influenza 
viruses replicate in their reservoir hosts [33, 34]. The two types of sialic acids, however, are 
present in human airways. Epithelial cells in the upper respiratory tract, including the trachea and 
bronchi, mainly express Sialyl α-2,6 Gal, while Sialyl α-2,3 Gal is enriched in the lower 
respiratory track, primarily in alveolar cells[35]. The different distribution of sialic acid receptors 
contributes to the host specificity of influenza viruses. Both the avian Sialyl α-2,3 Gal and the 
human Sialyl α-2,6 Gal present in the swine trachea [34], which is why swine serve as a mixing 
vessel for the reassortment of avian influenza virus and human influenza virus. New variants of 
IAVs, including the 2009 H1N1 pandemic strain are derived from swine. When avian IAVs 
develop the ability to bind the Sialyl α-2,6 Gal by reassortment, these viruses can infect humans 
and cause serious epidemic and even pandemic levels of transmission. 
After the binding of influenza HA to the Sialyl-galactose residue, the virus is engulfed in 
an endosome and a series of structural and chemical changes are initiated. First, host protease 
cleaves the HA at R329 and 1G into a fusion-competent form [36]. Virus acidification, driven by 
M2 ion channels, provides a low pH environment, which allows the HA to expose the fusogenic 
peptide [36, 37]. Fusogenic HA mediates the fusion of viral capsid and the endosomal 
membrane. The viral ribonucleoproteins (vRNPs) enter the host cell cytoplasm through the 
fusion pore, where the vRNP usurps the nuclear import machinery of the host cell to enter the 
nucleus [38]. 
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The single-stranded negative-sense RNA segments of the influenza genome are the 
templates both for the viral mRNA transcription and for the synthesis of complementary RNA 
(cRNA), which serves as the replication template to produce multiple vRNAs. The biochemical 
process of transcription and replication are distinct (Table 3). Transcription occurs prior to 
replication, which is initiated by the binding of viral polymerase (vPol) to the host eukaryotic 
polymerase II (ePol II) and is primed by the capped host pre-mRNA segments [39]. The host 
pre-mRNA primer is caught by PB2 and then cleaved by PA[40]. Viral mRNA is synthesized by 
PB1 using vRNA as the template, which then seizes the host ribosomes to express viral proteins. 
Replication is a two-step process and is primer-independent [40]: 1) cRNA is synthesized by 
PB1 and 2) new vRNA synthesis uses cRNA as the template. The rate of replication is much 
slower than the transcription [41]. 
After vRNA synthesis, PB1, PB2, PA, and NP binds to the vRNA to form the vRNP in 
the host nucleus. Similar to the import, the vRNP exploits the host nucleus export protein, 
namely exportin-1, to migrate into the host cytoplasm [38]. Surface proteins, including NA, HA, 
and M2, are inserted into the plasma membrane. The virion is assembled at the plasma 
membrane and nucleated driven by M1 proteins. Finally, NA cleaves the sialic acid from the 
glycoproteins, releasing the budding virus from the host cell. 
The Innate immune responses to IAV infection 
The innate immune responses that recognize and respond to IAVs are critical for antiviral 
immunity. Pathogen-associated molecular patterns (PAMPs) are recognized by pattern-
recognition receptors (PRRs), including surface PRRs, such as Toll-like receptors (TLRs) and 
cytosolic PRRs [42, 43]. For IAVs, TLR3 and TLR7 are the major functional surface PRRs. 
TLR3 recognizes dsRNA in the endosome of IAV infected cells, providing signals to restrict 
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viral replication and prime the adjacent cells, and expressing chemokines to recruit innate and 
adaptive immune cells[44-46]. TLR7 recognizes the ssRNA genomes contained in IAV virions, 
activates nuclear factor-κB (NF-κB) and IFN-regulatory factor 7 (IRF7) via MyD88 signaling to 
express type I interferons (IFNs), pro-inflammatory cytokines, and multifunctional interleukin 12 
(IL-12). Type I IFNs can directly interfere the viral replication, prime the adjacent cells, and 
enhance the cell-mediated immunity[47, 48]. Pro-inflammatory cytokines, including tumor 
necrosis factor (TNF) and IL-6, improve the immune cell function, but also result in the systemic 
symptoms of influenza[49]. IL-12 is the key factor to induce the TH1 responses[50]. It also 
promotes natural killer (NK) cells and T cells to release type II IFN (IFN!), which serves as a 
non-specific activator for many immune cells [50] (Table 4). TLR7 also plays an important role 
in antibody production [51, 52]. TLR7 deficiency leads to compromised early-B-cell response 
and lower level of HA-specific antibody production [53]. Administration of TLR7 agonists 
facilitate more robust immune responses to IAV infection in mice [54].  
Other PRRs, including retinoic acid-inducible gene I (RIG-I) and Nucleotide-binding 
oligomerization domain, Leucine rich Repeat and Pyrin domain containing Proteins (NLRPs) 
have roles in cytosolic PAMP recognition. RIG-I recognizes the replicated viral ssRNA bearing 
5'-triphosphate[55-57], activating NF-κB and IRF3 via mitochondrial antiviral-signaling 
(MAVS) [58]. IAV infection also stimulates the NLRP3 oligomerization. Oligomerized NLRP3 
recruits apoptosis-associated speck-like protein containing a CARD (ASC) and Caspase 1 to 
form an NLRP3 inflammasome, leading to caspase-1 activation and pro-inflammatory IL-1β and 
IL-18 secretion [59, 60]. Evidence also shows that ASC and Caspase 1 are indispensable in 
developing the adaptive immune responses against IAV infection[61].  
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Innate immune system reacts rapidly after the exposure to IAV and leads to early signs of 
influenza infection, including feverishness, fatigue, headaches, and myalgias, which are induced 
by pro-inflammatory cytokines [62]. During influenza infection, cytokines help with the antiviral 
process either by interfering viral replication or by enhancing the cell-mediated and/or humoral 
immune responses (Table 4). However, the rapid and excess production of cytokines leads to 
cytokine storm, which is the pathogenic sin for acute respiratory syndrome, tissue damages, and 
organ dysfunctions. Pro-inflammatory cytokines stand in the eye of the storm. TNF plays a key 
role in the cytokine storm, contributing to the morbidity of IAV infection by inducing 
hyperactive inflammation, tissue damage, and lung consolidation[63-65]. IFNs activate the IFN-
induced gene expression, which is indispensable for IAV clearance, nevertheless, excessive IFN 
signaling causes uncontrolled inflammation and irreversible lung tissue damage[66-69]. IL-1 and 
IL-18, which are the downstream products of NLRP3 inflammasome, are also responsible for the 
acute pulmonary immunopathology[70, 71]. However, IL-6 serves as a protective factor in the 
hyperinflammation by producing neutrophil survival and reducing the lung pathology[72, 73]. In 
addition, excessive chemokines can recruit superfluous immune cells to the site of infection, 
which exacerbates the detrimental inflammation[74].  
During IAV infection, the non-specific innate immunity is first initiated via PAMP-PRR 
recognition, priming the uninfected cells and inducing the specific and more efficient adaptive 
immunity. Innate immune responses play an important role in the early stage of infection to 
interfere viral replication and assist with viral clearance. However, the inflammation induced by 
innate immune responses contributes to immunopathology, and even can result in the mortality 
of influenza. 
The Adaptive Immune Responses to IAV Infection 
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The adaptive immune response typically takes 5-7 days to develop, providing a highly 
specific and efficient effect to restrict viral replication, clear the viruses, and develop memory to 
protect from re-infection. The humoral response is predominated by HA-specific antibody and 
NA-specific antibody. Anti-HA antibodies typically bind to the head domain of HA, which 
contains the receptor-binding site and is variable between IAV strains[75, 76]. These antibodies 
neutralize the viral infection either by blocking the IAV entry to the cell or by inducing the Fc 
receptor-mediated phagocytosis[77]. Some HA specific antibodies that bind to the HA stem 
domain, which is the conserved region, also have the protective effect via neutralizing viruses 
and inducing antibody-dependent cell-mediated cytotoxicity (ADCC) [78-80]. HA stem-binding 
antibodies are the major components of cross-reactive antibodies against influenza, and they 
have a broad-spectrum protection across IAV strains and even across both IAV and IBV [81-85]. 
Anti-NA antibodies also have protection against influenza infection by inhibiting the enzymatic 
activity. NA active site-binding antibodies that broadly neutralize multiple different IAV and 
IBV strains [86, 87]. Influenza infection also induces antibodies against NP, matrix proteins, and 
other virion components [75, 88-90].  Antibody responses are mount within 1-2 weeks after 
influenza infection. IgG is the dominant subtype of protective influenza-specific antibodies in 
lungs and serum, while IgA plays a more important role in mucosal protection at the entrance of 
infection, i.e., the respiratory tract [91, 92]. The antibody protection induced by natural infection 
of influenza can last for decades [75]. 
The clearance of infected cells requires a cellular response, mediated by CD4+ T cells 
and CD8+ T cells. Dendritic cells process and present the exogenous and endogenous influenza 
virus antigens in the class I and class II major histocompatibility complex (MHC) molecules to 
CD8+ and CD4+ T cells, respectively.  CD4+ T cells recognize the influenza epitope in the 
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context of class II MHC, further differentiating to Th1 cells to protect against viral infection 
[93]. Th1 cells produce IFN-γ which has the antiviral activity and can activate macrophages [94, 
95]. IAV-activated CD4+ T cells also produce IL-2 to stimulate CD8+ T cell proliferation and 
differentiation [96]. Activated and armed CD8+ T cells, also called cytotoxic T cells (CTLs), 
recognize the influenza peptide presented in class I MHC. CTLs can either directly kill the 
infected cell via cytolysis using preformed perforin and granzymes or induce apoptosis via 
Fas/FasL interaction[97]. Evidence shows that CTLs are more cross-reactive to different 
influenza strains compared to the antibodies[98]. However, the memory pool of CTLs that 
recognize IAVs contract within a few years, and the longevity of T cell memory after influenza 
infection is still unclear [99, 100]. Besides, dysregulated CTL can also accelerate the pulmonary 
immunopathology via its cytotoxic activity or pro-inflammatory cytokine secretion[101, 102].  
 Adaptive immunity is not initiated immediately after infection, but it is the most powerful 
defense. Neutralizing antibodies, which are highly specific to a certain IAV epitope, interfere the 
viral life cycle to slow down the spread of virions. CD4+ T cells predominantly differentiate to 
Th1 cells during IAV infection, providing sufficient IFN-γ to impede viral replication. 
Meanwhile, CD8+ T cells are activated and armed to specifically clear the IAV infected cells by 
direct contact and the cytotoxicity. In addition, adaptive immunity can develop long-term 
memories to prepare for the next exposure to the identical pathogen. However, the adaptive 
immune responses need to be well-regulated to avoid the drastic tissue damage. 
Animal Models to Study Influenza Pathogenesis 
The pathogenesis of IAV infection has been characterized in various mammalian animal 
models, including mice, rats, guinea pigs, ferrets, hamsters, and rhesus macaques [103]. Mice are 
the most commonly used model, and inbred mouse strains, including BALB/C, C57BL/6, and 
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DBA/2, are frequently used to study IAV pathogenesis via intranasal infection. DBA/2J mice are 
more susceptible to IAV infection compared to BALB/C and C57BL/6 mice [104, 105]. 
However, animal models for IBV pathogenesis are lacking because of the limited host 
range of IBV. Mice and ferrets have been used for IBV pathogenic models[106-108]. IBV must 
be adapted by serial passaging or inducing mutation to increase the infectivity in non-host 
animals[106-108]. 
Sex Difference in the Response to Influenza Infection 
Epidemiological evidence shows age-stratified sex differences in the morbidity and 
mortality of IAV infection both in pandemics and seasonal epidemics [109-113]. In children, the 
confirmed cases are significantly higher in boys than girls [111, 112]. While in adults, the male 
to female ratio (MFR) decreases and even reverses [111]. In the mouse models of IAV infection, 
females have greater morbidity and slower recovery than males [114-116]. This female bias in 
IAV disease pathogenesis is caused by sex steroid hormone-mediated greater inflammation and 
reduced activation of repair pathways [114-118]. For example, greater production of 
amphiregulin and testosterone production in males have been shown to independently protect 
male mice in H1N1 infection [114]. While amphiregulin promotes repair of damaged tissue 
caused by infection and immune-activation, testosterone dampens inflammation [117]. In female 
mice, infection with IAV disrupts their reproductive cycle and administration of estradiol, estriol, 
or progesterone can suppress the inflammatory response to protect them from severe 
pathogenesis [115, 118, 119]. Females produce more neutralizing antibodies, and the total 
antibody response against IAV is stronger in females than in males, which is also mediated by 
estradiol in female mice [116, 120]. While progesterone treatment reduces the adaptive immune 
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responses in female mice, compromising the protection from re-exposure[118]. And the cross 
protection of humoral immune response is greater in females compared to males [116].    
In IBV, sex differences in disease pathogenesis are age dependent. Generally, males are 
less likely to be infected with IBV [121]. In children, however, boys have a higher frequency of 
IBV infections than girls [122]. The hospitalization rate also is higher in males than in females, 
except for among young adults, age 18-39, in which females experience greater disease than 
males [25, 112, 123]. Females also tend to have a lower mortality from IBV infection [124].  
Comparing to IAV, there are fewer pathogenic studies of IBV infection due to the lack of 
suitable animal models. Recent study in female mice found that IBV infection induces severe 
diseases and decreases concentrations of progesterone and estradiol during pregnancy, 
suggesting that sex hormone can be disturbed by IBV infection [125]. Unpublished data from our 
collaborator Dr. Daniel Perez show greater morbidity in the male DBA/2J mice compared to the 
females infected with mouse-adapted B/Brisbane/60/2008 (Victoria lineage), which is different 
from IAV infection (see above).  
Therefore, to better understand the effect of biological sex on IBV infection, we 
established a pathogenetic model in male and female C57BL/6 mice. We compared the 
morbidity, lung viral kinetics, cytokine responses, and antibody production between male and 
female mice. Results were also compared with the published corresponding data of IAV.
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Table 1. Structural and functional differences in influenza A (IAV), B (IBV), C (ICV), and D 
(IDV) viruses. 
 
 IAV IBV ICV IDV 
Hemagglutinin HA HA 
HEF HEF 
Neuraminidase NA NA 
Polymerase PB1, PB2, PA PB1, PB2, PA PB1, PB2, PA PB1, PB2, PA 
Matrix protein M1 M1 M1 M1 










Nucleoprotein NP NP NP NP 
Nuclear export 
protein 
NS2/NEP NS2/NEP NS2/NEP NS2/NEP 
Non-structural 
protein 
NS1 NS1 NS1 NS1 
Hosts 
Avian, human, 
swine, horse, seals 
Human, seals Human Bovine, swine 
Receptors 












Table 2. Comparison of Victoria and Yamagata lineage influenza B viruses. 
 
 
Table 3. Comparison of the process for IAV transcription and replication. 
 
 
 Transcription Replication 
Timing Prior Posterior 





Host pre-mRNA primer Primer-independent 
ePol II 
dependence 
vPol activated by ePol II ePol II-independent 
Rate High Low 
 Victoria Yamagata 
Receptor α-2,3 and α-2,6 α-2,6 
Age distribution 
Younger,  
positively skewed unimodal 
Older, bimodal 
Hospitalization More severe Less severe 
Transmission More regional Broader 
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Table 4. Featured cytokines in influenza infection. 







Promote monocyte differentiation 
Promote B cell and T cell functions 
Tissue damage  Immediate  
IL-6 Macrophages 
Pro-inflammatory cytokine 
Promote monocyte differentiation 
Promote B cell and T cell 
differentiation 
Protect hyperinflammation 







Induce the release of IL-1 and IL-6 
Promote neutrophil and macrophage 
functions 
Tissue damage 





Upregulate IL-1 and TNF; 
downregulate type I IFN 
Enhance cell-mediated immunity 










Enhance TH2 immune response 
Regulate excessive inflammatory 
response 
Tissue repair Early stage 
IL-4 
TH2 CD4 T 
cells 
Promote B cell differentiation 
Reduce cell-mediated immunity 
Tissue repair Late stage 
IL-10 












Enhance cell-mediated immunity 
Upregulate chemotactic cytokines 
Tissue damage Immediate 
Type II 
IFN 
TH1 CD4 T 
cells, NK cells 
Antiviral cytokine 
Upregulate pro-inflammatory 
cytokines Promote DC activation 
Enhance cell-mediated and humoral 
immunity 









Adult (8-12 weeks) male and female C57BL/6 mice were purchased from Charles River 
Laboratories. All animals were housed at up to 5 mice per microisolator cage under standard 
biosafety level 2 housing conditions, with food and water provided ad libitum. All experiments 
were performed in compliance with the standards outlined in the National Research Council’s 
Guide to the Care and Use of Laboratory Animals. All animal procedures were approved by the 
Johns Hopkins Animal Care and Use Committee (MO18H250). All efforts were made to 
minimize animal suffering. 
Virus 
B/Brisbane/60/2008 with PB2 F406Y mutation (mt-B/Bris) virus was used in this study 
for infection and antibody titration. PB2 F406Y mutation was induced to B/Brisbane/60/2008 
virus by Dr. Daniel Perez to enhance the pathogenesis in mice. The working stock was generated 
by infecting Madin-Darby Canine Kidney (MDCK) cells at a multiplicity of infection (MOI) of 
0.01 and the infected cell supernatant was collected, centrifuged, and the virus containing 
supernatant was collected. The quantity of viruses is determined by units of tissue culture 
infectious dose (TCID50).  
Animal infection and processing 
Mice were anesthetized with ketamine (80mg/kg)/ xylazine (13mg/kg) cocktail injected 
intraperitonially and inoculated intranasally with 104 and 105 TCID50 units of 
B/Brisbane/60/2008 in 30uL of the virus in Dulbecco’s modified Eagles Medium (DMEM). For 
morbidity study, body mass and rectal temperature changes were daily recorded up to 14 days 
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post infection (dpi). For time course experiments, mice were randomly assigned to be euthanized 
at 1, 3, 5, and 7 dpi. Mice were anesthetized using ketamine–xylazine cocktail before retrobulbar 
bleeding. Blood was collected into heparinized tubes and was centrifuged to separated plasma. 
Plasma was stored at -80℃ and used to measure cytokines. Left lung and spleen were collected, 
snap-frozen and stored at -80℃. Right lung lobes were inflated and fixed with zinc-buffered 
formalin (Z-fix, Anatech, MI, USA) under a constant pressure of 25 cmH2O for at least 24 
hours. Plasma was also collected at 21 dpi to measure the antibodies. 
Lung virus titration 
Left lungs were homogenized in 500ul of serum-free DMEM. Infectious viral particles in 
the supernatants were detected using TCID50 assay. Lung samples were 10-fold serial-diluted 
and transferred into 96-well tissue-culture plates in six replicates to infect a confluent monolayer 
of MDCK cells. Plates were incubated at 32℃ for 6 days, fixed with 4% formaldehyde, and 
stained with naphthol blue black. Units of TCID50 were calculated based on the cytopathic 
effects (CPE) of influenza B virus. 
Detection of cytokines and chemokines 
Left lungs and spleens were homogenized in 500ul of serum-free DMEM, followed by 
centrifugation to remove the cellular debris. Cytokines and chemokines in lungs, spleens, and 
sera were measured using the Immune Monitoring 48-Plex Mouse ProcartaPlex™ Panel on 
Curiox DA-Bead DropArray platform according to the manufacturer’s instructions. The 
following analytes were quantified: granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-
CSF), IFN-a, IFN-g, IL-1a, IL-1b, IL-2, IL-2R, IL-3, IL-4, IL-5, IL-6, IL-7, IL-7Ra, IL-9, IL-
10, IL-12p70, IL-13, IL-15, IL-17A, IL-18, IL-19, IL-22, IL-23, IL-25, IL-27, IL-28, IL-31, IL-
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33, IL-33R, Leukemia inhibitory factor (LIF), CXCL1, CXCL2, CXCL5, CXCL10, CCL2, 
CCL3, CCL4, CCL5, CCL7, CCL11, TNFa, receptor activator of nuclear factor kappa-Β ligand 
(RANKL), B-cell activating factor (BAFF), Betacellulin, vascular endothelial growth factor 
(VEGF)-A, and Leptin. For analyses, the concentration of following analytes remained below the 
limit of detection at all time points and were excluded: IL-2R, IL-9, IL-19, IL-31, CXCL10, and 
Leptin in lungs, IL-9 in spleens, and IL-2, IL-3, IL-4, IL-7Ra, IL-13, IL-22, IL-27, LIF, 
Betacellulin, CXCL5, CCL3, and CCL5 in sera. Cytokine fold changes, i.e., the raw 
concentrations (pg/ml) relative to the geometric mean concentrations (pg/ml) of mock infected 
samples, were calculated to control for baseline sex differences.  
Detection of neutralizing antibodies 
Plasma neutralizing antibodies were detected using microneutralization assay with 
MDCK cells. Plasma samples were inactivated at 56℃ for 30 minutes and 2-fold serial-diluted 
to neutralize 50 TCID50 of influenza B virus for 1 hour at room temperature. The plasma-virus 
mixture was transferred into 96-well tissue-culture plates in quadruplicates and incubated for 24 
hours at 32℃ to infect MDCK cells. Following incubation, cell culture media were changed to 
remove the inoculum. Plates were incubated at 32℃ for another 5 days, fixed with 4% 
formaldehyde, and stained with naphthol blue black. The neutralizing antibody titers were 
calculated as the highest plasma dilution that eliminates the CPE in at least 50% of the wells. 
 
Statistical analyses 
Longitudinal morbidity measures, including body mass and temperature, were analyzed 
with repeated-measures two-way ANOVAs. Longitudinal measures with unmatched samples, 
including lung virus titers and cytokine fold changes, were analyzed using unmatched two-way 
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ANOVAs with Bonferroni post hoc correction for multiple comparisons. Single time point 
neutralizing antibody titers were analyzed using Student t-tests. Comparisons were considered 




Morbidity from B/Brisbane/60/2008 is greater in males than females 
To investigate sex differences in the outcome of IBV infection, adult male and female 
C57BL/6 mice were inoculated with 104 or 105 TCID50 of B/Brisbane/60/2008 and were 
monitored for 15 days for changes in body mass and rectal temperature as well as death (Figure 
1A). Infection with 104 TCID50 did not cause observable disease in either males or females, 
while infection with 105 TCID50 resulted in pathogenesis in both sexes (Figure 2A and 2B). 
Body mass loss was observed after 4-5 days post infection (dpi), and recovery began at 6-7 dpi 
(Figure 2A). Male mice experienced greater morbidity, i.e., had greater body mass loss and 
hypothermia, compared to the females (Figure 2A and 2B, p < 0.05). No mortality was observed 
in female mice, while one male died at 8 dpi among mice infected with 105 TCID50.  
Male mice have greater titers of B/Brisbane virus in lungs than female mice  
To determine if male biased disease severity was caused by a reduced ability of males to 
control virus replication, lungs were collected at 1, 3, 5, or 7 dpi for virus titration (Figure 1B). 
A significant main effect of sex was observed, in which lung viral titers peaked in 3 and 5 days 
after IBV infection, with a consistent trend that males had greater titers than females (Figure 2C, 
p < 0.05). There also was a significant interaction between sex and dpi, in which at 5 dpi, the 
difference of IBV titers in lungs was maximized (Figure 2C, p < 0.05). These data illustrate that 
that males compared with females had a reduced ability to control virus replication. 
Male mice developed an aberrant local inflammatory response 
To understand the possible factors leading to the male bias in pathogenesis and viral 
clearance, pulmonary, splenic, and peripheral cytokine concentrations were measured at 3 (i.e., 
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during peak virus replication) and 7 (i.e., after virus clearance) dpi. Because there can be 
baseline sex differences associated with instillation of vehicle into the lungs [115], sex difference 
in the baseline concentrations of cytokines were controlled by analyzing the fold change relative 
to mock infected male or female mice. In response to B/Brisbane infection, both males and 
females showed systemic immune activation during the first week after IBV infection, as is 
reflected in the increased expression of IFN-a, IFN-g, IL-12p70, IL-18, CXCL2, and CXCL5 in 
the spleen and IFN-a, IL-1b, IL-6, and IL-18 in serum (Figure 3, Figure 4, and Supplemental 
Table 1, Supplemental Table 2). Peripheral induction of cytokines showed rare sex differences. 
In the spleen, females expressed greater IL-28 than males at 3 dpi, while males expressed greater 
IL-23 and CXCL10 at 7 dpi (Figure 3). In the serum, significant sex differences were only 
observed at 7 dpi, with greater expression of IL-9, IL-33, CCL7, and CCL11 in females (Figure 
4). 
There were greater differences between males and females at the site of infection (Figure 
5). At 3 dpi, females presented with greater concentrations of IL-1a, IL-1b, and IL-12p70 in 
lungs than males, suggesting that females had a more rapid local innate response during peak 
virus replication (Figure 6A, 6B, and 6C, p < 0.05). In contrast, at 7 dpi, the pulmonary 
concentrations of IFN-g, IL-3, IL-6, CCL2, CCL3, and CCL4, were significantly greater in in 
lungs from male than female mice (Figure 6D, 6E, 6F, 6I, 6J, and 6K, p < 0.05). In addition, 
there was a trend in IFN-a and TNFa that showed greater inductions in females at 3 dpi but in 
males at 7 dpi (Figure 6M and 6N). Taken together, these data suggest that while both males and 
females experience appropriate immune activation following infection, females develop more 
rapid cytokine responses in the presence of virus and males sustain cytokine responses after virus 
has been cleared.  
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During the recovery phase of IBV infection, females produced greater neutralizing 
antibody titers than males 
Recovery from IBV infection requires induction of adaptive immune responses, which 
contribute to viral clearance and memory responses that protect against re-infection. To evaluate 
sex differences in the humoral response following IBV infection, serum was collected at 21 dpi 
from IBV-infected male and female mice (Figure 1A). After B/Brisbane infection, female mice 
produced significantly greater neutralizing antibody titers than male mice (Figure 7, p < 0.05). 
The greater neutralizing antibody titers suggest stronger humoral responses in females, which 
may contribute to the better outcome in females during the primary IBV infection, and provide 




































In this study, we established a IBV pathogenesis model using adult C57BL/6 mice. Sex 
differences were observed, with worse symptoms and greater virus replication and slower 
clearance of virus from the lungs in male mice. Male mice also had slower pulmonary induction 
of cytokines in the lungs during peak virus replication, but then sustained and even elevated 
pulmonary cytokine responses after virus had been cleared from the lungs. Females also 
produced greater antiviral antibody responses than males, which could be significant for 
protection following re-infection. 
Sex biases are observed among many different host species ranging from mice to humans 
and in response to many pathogens [126]. Generally, the susceptibility to infection is greater for 
males than females, which could be explained by the sex disparities in gene expression, immune 
responses, and behavior [127]. Considerable evidence shows that factors associated with 
biological sex, including sex steroid and growth factor modulation of immune responses, affect 
IAV pathogenesis (Table 5). Sex steroids impact the pathogenesis and outcomes of viral 
infection by modulating inflammation, antibody production, or tissue repair. However, these 
mechanisms result in worse outcomes in females following IAV infection, whereas our study 
showed a male bias in IBV pathogenesis. Therefore, more comprehensive studies are necessary 
to understand the role of biological sex in the response to IBV infection. 
In our study, after the infection of 105 TCID50 of B/Brisbane/60/2008, male mice 
experienced significantly more severe disease than females. Remarkably, the outcomes of IAV 
infection are generally worse in reproductive aged adult females in both humans and mice, which 
is opposite to our observation in IBV infection [114, 115, 128, 129]. In fact, a number of studies 
from our laboratory using diverse H1N1 and H3N2 IAV viruses have shown that adult C57BL/6 
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female mice experience greater morbidity than male mice (Robinson et al. 2011, Lorenzo et al. 
2011, Vermillion et al. 2018).  Sex differences in the pathogenesis of IAV are not associated 
with differences in the ability to control virus replication, because sex differences in pulmonary 
infectious virus titers have not been observed [114, 115, 129]. Our IBV data, however, show a 
significant sex effect in pulmonary virus replication kinetics, with male lungs containing higher 
titers of virus than female lungs.  
Innate responses to replicating virus are integral for control of viral infection. During 
peak viral replication, i.e. at 3 dpi, females had greater concentrations of IL-1a, IL-1b, and IL-
12, which are important for immune responses activation and modulation of T cell differentiation 
[93, 130-132]. At 7 dpi after B/Bris infection, when the virus had been cleared, males presented 
with significantly greater concentrations of IFN-g, IL-6, CCL2, CCL3, and CCL4 in lungs 
compared to females. Noticeably, IFN-g, IL-6, and CCL2 are higher in female lungs than in 
males after IAV infection [129, 133]. Therefore, the sex difference in the continuous production 
of IFN-g, IL-6, and CCL2 might be the direct reason for the sex-biased outcome. To test these 
hypotheses, IFN-g knockout male and female mice should be included in the future work, to see 
if the sex dimorphisms in viral clearance and in disease outcomes could be neutralized by IFN-g 
deficiency. IL-6 or CCL2 knockout mice would also help to interpret the mechanisms of sex-
biased immunopathogenesis. IFN-a and TNFa also showed a trend in the induction, which was 
greater in females at 3 dpi, while in males at 7 dpi. The aberrant cytokine induction may result in 
compromised viral clearance and more severe tissue damage in males.  
Successful recovery from influenza infection relies on the immune system to find a 
balance among antiviral defense, immunopathogenesis, and tissue repair. In our study, at 3 dpi 
after IBV infection, pro-inflammatory cytokines, including IL-1b, IL-6, and IFN-a, were 
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increased in serum of both sexes, inducing systematic symptoms such as hypothermia and 
fatigue[130, 134, 135]. Besides, these cytokines are essential for the activation of immune 
responses by modulating monocyte differentiation, activating adaptive responses, and promoting 
antibody isotype switching [73, 131, 136-138]. The antiviral function of IFN family is also 
important in defense against influenza virus [139]. In lungs, IFN-a and IFN-g were significantly 
induced to suppress viral replication at 3 dpi. Meanwhile, chemokines were elevated to attract 
the immune cells to the infection site. However, overproduction of pro-inflammatory cytokines 
and excessive cytotoxic effects from NK cells and CD8+ T cells lead to tissue damage[102]. At 
the end of viral clearance, a downregulation on the expression of pro-inflammatory cytokines 
and chemokines is inevitable to avoid further damage. At 7 dpi, the levels of IFN-g, IL-6, and 
CCL2, CCL3, CCL4 in male mice were significantly higher than in female mice, resulting in 
worse symptoms and longer courses. Interestingly, although IL-6 causes tissue damage, it has 
been identified to suppress the hyper-inflammation[73]. Therefore, the elevation of IL-6 may 
serve as a signal for hyper-inflammation. During influenza pathogenesis, IL-12 and IL-33 have 
been shown to promote tissue repair. We observed higher level of IL-12 in female lungs at 3 dpi, 
and elevated IL-33 in female serums at 7 dpi, which may contribute to the faster recovery of 
females. 
As IBV is causing greater circulation and diseases, prophylaxis for IBV needs more 
attention. Males tend to have lower antibody responses than females following influenza 
vaccination [140-143], which might be attributed to the sex disparity in the global gene 
expression in B cells [144]. In our study, females produced greater neutralizing antibody titers at 
21 dpi after IBV infection, indicating poorer humoral responses to IBV antigens in males, which 
might be explained by the distinct process of B cell proliferation and differentiation in males and 
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females. In short, males have lower immunity to IBV antigens but suffer greater diseases from 
IBV infection. The effects of biological sex on IBV pathogenesis and vaccine responses in 
humans should be explored. Influenza vaccination rate in males, especially in children and 
elderly, should be taken seriously.  
In summary, our data suggest that males experience more severe disease than females 
following IBV infection, which may result from impaired viral clearance and compromised 
innate and adaptive immune responses. To date, studies on IBV pathogenesis are still lacking, 
and there is no published data comparing male and female responses using animal models. Our 
study established a successful IBV pathogenic mouse model using mouse-adapted B/Brisbane 
virus (Victoria lineage) in adult male and female C57BL/6 mice. Other strains of IBV Yamagata 
lineage, and other mouse strains might be applied to repeat and compare. A comprehensive 
understanding of IBV pathogenesis in different sexes will help with more precise influenza 
prophylaxis and treatment. The mechanisms on how sex steroids and sex chromosomal genes 
regulate the responses to IBV require further investigation. Besides, this study only focused on 
the sex disparity in reproductive aged adult mice. Juvenile and aged mice should also be included 
to identify the age-sex interaction in future studies. 
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Table 5. The effect of sex associated factors on influenza pathogenesis. 
 
 
Factor Type Effect Function 
Amphiregulin Growth factor Protective Promote tissue repair 
Testosterone Sex steroid Protective Reduce inflammation 
Estradiol Sex steroid Protective 
Reduce inflammation; promote 
antibody production 
Estriol Sex steroid Protective Reduce inflammation 
Progesterone Sex steroid Protective; harmful 
Reduce inflammation; promote tissue 
repair; reduce adaptive responses 
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FIGURE AND TABLE LEGENDS 
 
Table 1: Structural and functional differences in influenza A (IAV), B (IBV), C (ICV), and 
D (IDV) viruses. 
Table 2: Comparison of Victoria and Yamagata lineage influenza B viruses. 
Table 3: Comparison of the process for IAV transcription and replication. 
Table 4: Featured cytokines in influenza infection. 
Table 5: The effect of sex steroids on influenza pathogenesis. 
Figure 1: Experimental designs. 
(A) Adult male and female C57BL/6 mice were intranasally inoculated with 30μl 104 or 105 
TCID50 of mouse-adapted B/Brisbane/60/2008 viruses. The mice were then monitored 15 days in 
body mass and rectal temperature. At 21 days post infection (dpi), mice were euthanized to 
collect blood for microneutralization assays (n = 10 or 20/group).  (B) Adult male and female 
C57BL/6 mice were intranasally inoculated with 30μl 105 TCID50 of mouse-adapted 
B/Brisbane/60/2008 viruses. The mice were euthanized at 1, 3, 5, or 7 dpi to collect lung samples 
for virus titration (n = 9-12/group). At 3 and 7 dpi, mice were euthanized to collect lung, spleen, 
and serum for cytokine quantification (n = 10-12/group).  
Figure 2: Morbidity and lung virus titers of B/Brisbane infected adult male and female 
C57BL/6 mice. 
Adult male and female C57BL/6 mice were intranasally inoculated with 30μl 104 or 105 TCID50 
of mouse-adapted B/Brisbane/60/2008 viruses. Loss of body mass (A) and rectal temperature (B) 
were measured for 15 days, as correlates of morbidity. Data represents Means ± Standard Error 
of Mean from four groups (n=10 or 20/group). Infectious virus was measured in the lungs by 
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TCID50 at 1, 3, 5, or 7 dpi (C; n = 9–12/group/time-point). Significant differences between males 
and females are denoted by asterisks (* p < 0.05). 
Figure 3: Cytokine fold change profile in spleens. 
Adult male and female C57BL/6 mice were intranasally inoculated with 30μl 105 TCID50 of 
mouse-adapted B/Brisbane/60/2008 viruses (n = 10-12/group) or mock-infected (n = 9/group). 
At 3 and 7 dpi, spleens were harvested and homogenized. The cell-free supernatants were used to 
quantify 48 cytokine analytes. The color gradient of heatmap (A) represents the log10 fold change 
in splenic cytokine concentrations relative to respective mock-infected controls. The radar maps 
discriminate male and female differences at 3 dpi (B) and 7 dpi (C) in the log10 fold change of 
splenic cytokine concentrations relative to respective mock-infected controls. Significant main 
effects of sex are denoted by asterisks (* p < 0.05). Significant differences between males and 
females at 3 dpi are denoted by diesis (⧧ p < 0.05). Significant differences between males and 
females at 7 dpi are denoted by pound (# p < 0.05).	
Figure 4: Cytokine fold change profile in sera. 
Adult male and female C57BL/6 mice were intranasally inoculated with 30μl 105 TCID50 of 
mouse-adapted B/Brisbane/60/2008 viruses (n = 10-12/group) or mock-infected (n = 9/group). 
At 3 and 7 dpi, blood was collected, and serum was separated to quantify 48 cytokine analytes. 
The color gradient of heatmap (A) represents the log10 fold change in serum cytokine 
concentrations relative to respective mock-infected controls. The radar maps discriminate male 
and female differences at 3 dpi (B) and 7 dpi (C) in the log10 fold change of cytokine 
concentrations relative to respective mock-infected controls. Significant main effects of sex are 
denoted by asterisks (* p < 0.05). Significant differences between males and females at 3 dpi are 
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denoted by diesis (⧧ p < 0.05). Significant differences between males and females at 7 dpi are 
denoted by pound (# p < 0.05).	
Figure 5: Cytokine fold change profile in lungs. 
Adult male and female C57BL/6 mice were intranasally inoculated with 30μl 105 TCID50 of 
mouse-adapted B/Brisbane/60/2008 viruses (n = 10-12/group) or mock-infected (n = 9/group). 
At 3 and 7 dpi, lungs were harvested and homogenized. The cell-free supernatants were used to 
quantify 48 cytokine analytes. The color gradient of heatmap (A) represents the log10 fold change 
in pulmonary cytokine concentrations relative to respective mock-infected controls. The radar 
maps discriminate male and female differences at 3 dpi (B) and 7 dpi (C) in the log10 fold change 
of cytokine concentrations relative to respective mock-infected controls. Significant main effects 
of sex are denoted by asterisks (* p < 0.05). Significant differences between males and females at 
3 dpi are denoted by diesis (⧧ p < 0.05). Significant differences between males and females at 7 
dpi are denoted by pound (# p < 0.05). 
Figure 6: Sex difference in the induction of pulmonary cytokines after B/Brisbane 
infection. 
Adult male and female C57BL/6 mice were intranasally inoculated with 30μl 105 TCID50 of 
mouse-adapted B/Brisbane/60/2008 viruses (n = 10-12/group) or mock-infected (n = 9/group). 
At 3 and 7 dpi, lungs were harvested and homogenized. The cell-free lung supernatants were 
used to quantify 48 cytokine analytes. IFN-g (A), IL-1a (B), IL-1b (C), IL-3 (D), IL-6 (E), IL-
12p70 (F), CXCL1 (G), CXCL2 (H), CCL2 (I), CCL3 (J), CCL4 (K), and Betacellulin (L) 
showed significant male and female difference in fold change at either 3 dpi or 7 dpi. IFN-a (M) 
and TNFa (N) showed a trend but without significance. Data represent Means ± Standard Error 
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of Mean of the analytes fold change relative to mock infected mice. Significant differences 
between males and females are denoted by asterisks (* p < 0.05). 
Figure 7: Neutralizing antibody titers in the serum at 21 dpi. 
Adult male and female C57BL/6 mice were intranasally inoculated with 30μl 105 TCID50 of 
mouse-adapted B/Brisbane/60/2008 viruses (n = 10-12/group). Neutralizing antibody titers were 
measured at 21 dpi. Significant differences between males and females are denoted by asterisks 
(* p < 0.05). 
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Supplemental Tables 
Supplemental Table 1. Raw cytokine concentrations in spleens. 
dpi 3 7 
Sex Male Male 
ID 1 2 3 4 5 6 7 8 9 10 11 12 24 25 26 27 28 29 30 31 32 33 
BAFF  615.6 31.85 352 31.85 2462.5 126.47 4791.49 4791.49 6715.31 957.81 2462.5 2462.5 14775 126.47 2462.5 2462.5 14775 6715.31 9850 4791.49 14775 2462.5 
G-CSF  18.65 95.67 95.67 47 92.41 92.41 92.41 47 92.41 108.99 92.41 47 47 47 47 47 92.41 92.41 92.41 47 92.41 1737.5 
GM-CSF 158.1 576.1 576.1 183.6 927.2 268.5 268.5 3055.4 135.0 702.2 268.5 927.2 135.0 268.5 135.0 135.0 3055.4 135.0 1862.7 927.2 927.2 927.2 
IFN-α 1017.3 695.1 287.4 1027.6 920.0 3406.2 1838.6 920.3 1838.6 2641.5 920.0 920.0 2641.5 4155.4 920.0 920.0 920.0 1838.6 3406.2 920.3 9463.1 1838.6 
IFN-γ 38.4 46.0 455.6 265.1 264.2 1296.3 1296.3 264.2 1945.0 24.6 104.0 1945.0 239.8 264.2 296.9 1945.0 1296.3 104.0 264.2 1296.3 296.9 239.8 
IL-1α 722.0 575.1 753.2 319.0 1677.2 837.0 1204.7 1204.7 1677.2 1093.5 837.0 1204.7 7435.2 3265.4 837.0 3265.4 3265.4 3265.4 1677.2 837.0 3265.4 837.0 
IL-1β 237.3 22.0 188.0 22.0 113.0 113.0 224.7 224.7 224.7 27.0 681.8 113.0 432.7 113.0 224.7 113.0 113.0 113.0 113.0 113.0 224.7 113.0 
IL-2 41.2 91.9 94.0 187.5 225.4 225.4 113.0 1661.6 225.4 103.4 852.4 113.0 510.9 225.4 225.4 225.4 113.0 23.9 1661.6 113.0 113.0 113.0 
IL-2R 62.66 75.89 38 38 11.56 11.56 39.92 26.35 39.92 101.63 11.56 67.99 11.56 39.92 11.56 99.04 67.99 561.92 39.92 11.56 39.92 39.92 
IL-3 24.15 20.52 236.07 20.52 46.6 2.43 115.58 115.58 115.58 88.01 115.58 77.96 46.6 21.39 46.6 46.6 46.6 77.96 46.6 46.6 115.58 210.7 
IL-4 43 264 133 133 1090 1090 1090 1090 1090 160 1090 1090 545 1090 545 3606 1090 545 1090 545 1090 1090 
IL-5 237 22 22 43.28 23 44.56 800.98 44.56 44.56 44.56 1611.62 415.62 800.98 800.98 23 415.62 44.56 1200.23 44.56 44.56 44.56 44.56 
IL-6 1110 2548 112 112 288 5800 4279 5800 5800 1110 5800 5800 288 4279 4279 4279 288 288 5800 4279 4279 5800 
IL-7 2908 1185 3656 1185 255 5125 5125 5125 6922 247 20500 3556 5125 6922 6922 6922 3556 255 9328 6922 9328 5125 
IL-7Rα 342 751 2597 751 3750 4203 19950 19950 3325 683 19950 19950 19950 19950 716 4203 4748 6828 3325 19950 19950 3325 
IL-10 786 531 266 531 2152 7681 7681 6544 2152 2360 2152 2152 27952 9575 2152 10522 6544 7681 6544 6544 1077 11530 
IL-12p70 16 136.7 16 30.22 60 629.09 60 60 119.39 23 60 629.09 119.39 119.39 60 629.09 629.09 136.7 119.39 119.39 60 629.09 
IL-13 66.81 131.31 131.31 131.31 124 246.95 713.73 124 464.08 311.74 124 124 989.92 124 124 124 124 464.08 713.73 74.13 246.95 124 
IL-15/IL-15R 252.85 200.69 200.69 101 148.4 253.94 253.94 253.94 148.4 252.85 148.4 253.94 148.4 148.4 148.4 148.4 148.4 253.94 148.4 148.4 75 266.41 
IL-17A  294 575 2917 575 478 4700 126 126 741 209 1174 126 1174 294 294 64 126 478 478 64 64 7050 
IL-18  130 306 1375 306 130 52226 130 14206 3506 130 5416 3506 14206 913 5416 5416 10705 5416 913 2018 5416 7797 
IL-19 14568 9087 9087 9087 35928 13353 8521 26706 35928 8263 26706 42933 35928 13353 26706 42933 35928 26706 26706 26706 13353 58476 
IL-22  263 377 377 377 207 207 414 414 414 207 414 207 2018 207 58 13433 58 207 414 414 414 207 
IL-23 2435 298 298 5346 572 4874 6033 2841 2841 323 7295 3812 3812 10152 6033 8666 6033 10152 4874 2841 4874 4874 
IL-25 413 101 406 101 180 982 982 180 359 413 56 359 982 359 180 3535 1297 2251 982 669 359 982 
IL-27 133 56 448 56 1854 135 351 698 351 133 135 1194 56 698 56 9984 698 56 698 135 135 698 
IL-28 12634 1202 21752 4575 54025 216100 216100 216100 71043 5787 71043 172439 71043 2738 89993 71043 54025 89993 138889 138889 2738 216100 
IL-31 10504 3680 3680 4181 2666 7144 7144 2666 10650 3790 2666 7144 5195 5195 2666 14048 10650 8929 7144 7144 7144 10650 
IL-33 11125 43999 11681 5841 9755 44500 32412 55530 44500 13114 55530 40542 44500 36747 44500 55530 36747 66733 49171 36747 9755 267000 
IL-33R 134 3557 279 279 3063 6125 27126 27126 3063 1732 3063 5050 40690 3063 27126 40690 6125 27126 6125 5050 27126 27126 
LIF 21.94 206.9 131.37 131.37 102.66 102.66 52 249.68 168.52 11 49.03 102.66 49.03 102.66 102.66 52 102.66 52 102.66 52 52 102.66 
M-CSF 21.22 1.95 13.39 1.95 31.59 91.48 148 31.59 91.48 21.22 91.48 148 308.84 91.48 91.48 801.34 91.48 308.84 91.48 91.48 46 46 
RANKL 130.5 54.7 70.9 54.7 127.6 279.0 2235.1 503.6 279.0 97.6 381.0 822.8 1026.1 503.6 127.6 822.8 279.0 503.6 1263.9 1026.1 195.3 279.0 
TNFα 649.97 99 99 99 166.73 166.73 84 84 84 84 493.5 166.73 84 493.5 166.73 166.73 166.73 166.73 321.14 166.73 166.73 166.73 
CXCL5 763 3092 282 282 10005 2756 2756 1378 11154 148 2756 10005 73200 2756 8581 73200 10005 18614 14210 15233 12200 11154 
CCL11 1082 4275 2850 4275 4275 2850 4275 4275 2850 4275 2850 713 941 2850 2850 4275 713 4275 941 4275 713 2850 
CXCL1 1119 64 64 126 577 212 212 577 1100 98 212 302 212 143 143 143 143 143 302 143 143 302 
CXCL10 605 6 6 4 1710 1710 1710 1710 1710 427 1710 1710 1138 1710 1710 1138 1710 1710 1710 1710 1710 1138 
CCL2 1045 104 536 268 288 288 574 2088 3529 1918 288 288 574 574 574 288 574 3529 288 574 288 574 
CCL7 1646 737 31 31 825 825 647 1049 1859 821 647 647 1859 647 825 4950 1440 4950 825 1049 1440 4950 
CCL3 46.71 53.28 45.85 38.52 277.79 132.92 154.13 93.75 154.13 107.86 93.75 132.92 75.72 176.47 176.47 433.97 306.28 224.67 224.67 93.75 545.3 132.92 
CCL4 37.49 67.19 67.19 67.19 14.91 14.91 14.91 8 110.78 64.55 30.94 14.91 14.91 14.91 30.94 313.81 14.91 195.6 52.04 4.02 14.91 30.94 
CXCL2 18.29 43.24 22 22 73.87 73.87 73.87 73.87 73.87 49.47 206.92 73.87 143.32 73.87 73.87 887.18 143.32 380.99 206.92 206.92 206.92 73.87 
CCL5 797.9 308.1 171.7 202.3 414.7 436.2 669.6 1298.4 639.7 1122.9 801.7 700.8 1243.0 801.7 838.1 7154.4 956.6 1090.6 838.1 956.6 583.1 1416.8 
Betacellulin 243.21 60 367.73 367.73 71 140.65 71 403.86 979.77 452.46 300.63 537.04 140.65 140.65 71 140.65 71 537.04 37.98 300.63 37.98 140.65 
Leptin 1203 13031 13031 13031 6661 3331 6661 3331 3331 1508 35157 3331 3331 20462 3331 14797 3331 20462 3331 6661 3331 14797 





Continued Supplemental Table 1 
dpi 3 7 
Sex Female Female 
ID 13 14 15 16 17 18 19 20 21 22 23 34 35 36 37 38 39 40 41 42 43 
BAFF  823.55 174.2 352 2462.5 14775 4791.49 2462.5 2462.5 4791.49 2462.5 4791.49 4791.49 4791.49 14775 9850 14775 64 14775 14775 3465.95 4791.49 
G-CSF  10 95.67 95.67 2940.64 92.41 47 92.41 92.41 92.41 92.41 47 92.41 92.41 92.41 92.41 1059.94 47 47 92.41 92.41 47 
GM-CSF 702.2 183.6 684.7 927.2 927.2 135.0 135.0 927.2 135.0 135.0 927.2 927.2 135.0 135.0 927.2 927.2 135.0 135.0 927.2 135.0 135.0 
IFN-α 1017.3 144.0 1343.2 1838.6 920.0 1838.6 1838.6 920.3 1838.6 1838.6 1838.6 3406.2 1838.6 1838.6 1838.6 7909.2 1838.6 3406.2 920.0 7146.6 4155.4 
IFN-γ 11.4 46.0 670.2 1296.3 1296.3 264.2 296.9 1296.3 264.2 1296.3 1945.0 1945.0 264.2 1945.0 1296.3 1296.3 264.2 104.0 104.0 264.2 104.0 
IL-1α 319.0 676.6 753.2 19989.0 19989.0 138.5 837.0 1677.2 837.0 837.0 3265.4 837.0 837.0 1677.2 1677.2 7435.2 1677.2 19989.0 19989.0 1677.2 837.0 
IL-1β 22.0 188.0 22.0 113.0 113.0 113.0 113.0 224.7 224.7 113.0 68.5 224.7 224.7 113.0 224.7 113.0 113.0 113.0 113.0 113.0 113.0 
IL-2 41.2 386.5 187.5 225.4 113.0 510.9 225.4 225.4 225.4 225.4 225.4 225.4 225.4 225.4 225.4 23.9 852.4 23.9 852.4 510.9 225.4 
IL-2R 62.66 38 38 11.56 53.67 11.56 11.56 39.92 11.56 11.56 6 11.56 11.56 83.07 39.92 11.56 26.35 6 11.56 6 11.56 
IL-3 88.01 20.52 336.62 46.6 46.6 46.6 115.58 46.6 46.6 2.43 46.6 2.43 2.43 159.72 46.6 46.6 115.58 2.43 210.7 2.43 46.6 
IL-4 160 57 264 1090 545 1090 1090 1090 1090 1090 3606 1090 545 545 1090 3606 1090 1090 1090 1090 545 
IL-5 237 43.28 476.72 1611.62 800.98 1200.23 800.98 44.56 800.98 44.56 23 44.56 44.56 415.62 800.98 23 44.56 44.56 800.98 1611.62 44.56 
IL-6 1110 112 2548 5800 4279 288 4279 3320 5800 4279 288 4279 4279 288 4279 288 5800 288 6499 5800 5072 
IL-7 2908 5126 4444 20500 6922 9328 3556 5125 5125 5125 20500 6922 5125 255 255 255 255 5125 5125 255 255 
IL-7Rα 342 376 4001 3750 2854 4203 716 19950 19950 2854 3325 13300 716 5501 5501 19950 716 5501 5501 19950 19950 
IL-10 1571 266 266 8647 7681 7681 2152 7681 2152 6544 7681 2152 2152 2152 10522 2152 2152 11530 8647 6544 2152 
IL-12p70 23 157.67 120.67 629.09 945 119.39 60 60 102.41 629.09 629.09 119.39 60 629.09 945 945 119.39 102.41 629.09 60 102.41 
IL-13 21.46 131.31 30.7 124 124 124 124 124 124 124 124 124 124 1288.91 246.95 124 124 124 124 124 246.95 
IL-15/IL-15R 101 200.69 101 253.94 253.94 148.4 148.4 148.4 253.94 148.4 278.1 148.4 148.4 148.4 253.94 75 148.4 148.4 75 148.4 148.4 
IL-17A  147 575 575 64 1174 126 478 478 478 478 126 126 478 64 1174 1174 478 741 64 64 478 
IL-18  130 153 1375 18368 29008 18368 2018 29008 3506 5416 10705 23273 2018 29008 35671 23273 5416 7797 14206 2018 2018 
IL-19 8263 9087 9087 42933 48780 26706 26706 35928 26706 26706 35928 13353 26706 13353 48780 35928 26706 8521 26706 26706 26706 
IL-22  525 377 1013 207 207 414 207 2018 414 1121 414 207 207 207 414 58 207 207 5539 414 1121 
IL-23 298 298 596 7295 8666 7295 4874 7295 2841 10152 2841 3812 1144 3812 3812 4874 1144 4874 4874 1955 2841 
IL-25 413 406 101 1614 359 359 982 359 982 982 359 669 359 180 180 669 359 1614 982 982 982 
IL-27 133 110 110 698 6404 698 56 698 56 351 351 27 135 1194 56 135 135 6404 698 135 27 
IL-28 11573 21752 21752 324150 324150 71043 216100 216100 216100 216100 216100 54025 54025 2738 2738 54025 54025 89993 2738 37340 54025 
IL-31 3790 3680 2338 7144 1334 2666 2666 2666 2666 2666 7144 7144 2666 7144 7144 10650 2666 5195 14048 7144 2666 
IL-33 3503 11681 24685 55530 55530 32412 36747 36747 36747 44500 55530 44500 9755 44500 40542 44500 36747 9755 36747 36747 44500 
IL-33R 1732 279 279 27126 6125 3063 3063 3063 6125 6125 27126 27126 6125 6125 6125 6125 6125 40690 27126 6125 3063 
LIF 105.66 131.37 131.37 52 52 52 52 102.66 249.68 49.03 52 52 52 52 249.68 52 52 102.66 52 52 102.66 
M-CSF 21.22 13.39 13.39 202.74 202.74 91.48 91.48 46 202.74 46 46 91.48 46 46 46 46 91.48 31.59 308.84 46 46 
RANKL 212.4 28.6 28.6 503.6 381.0 279.0 503.6 649.8 279.0 127.6 1263.9 127.6 279.0 381.0 503.6 33.5 381.0 279.0 195.3 33.5 127.6 
TNFα 649.97 197.37 400.69 493.5 701.85 84 166.73 166.73 166.73 321.14 493.5 166.73 166.73 166.73 166.73 84 166.73 166.73 166.73 166.73 166.73 
CXCL5 1635 2187 3092 48800 73200 10005 2756 8581 2756 2756 18614 14210 10005 21345 14210 73200 16295 73200 13207 11154 16295 
CCL11 938 2850 713 2850 80 713 4275 2850 4275 713 4275 4275 158 941 4275 4275 713 2850 4275 713 713 
CXCL1 72 64 356 302 212 577 143 39 419 302 302 143 143 143 143 143 302 143 143 143 87 
CXCL10 1053 6 6 1710 1710 263 1710 1710 1138 1710 1710 1710 1138 1710 1710 1710 1138 1710 1710 1710 61 
CCL2 523 268 268 288 288 288 288 288 288 288 288 288 288 288 574 574 288 288 288 288 288 
CCL7 253 31 16 4950 4950 825 191 647 1049 96 1049 1049 647 1049 3300 4950 551 3300 1049 647 825 
CCL3 56.28 23.68 53.28 176.47 93.75 58.66 93.75 93.75 132.92 93.75 176.47 75.72 93.75 250.6 336.1 277.79 75.72 585.61 399.91 93.75 132.92 
CCL4 64.55 100.68 67.19 52.04 14.91 52.04 52.04 52.04 14.91 8 14.91 8 14.91 52.04 52.04 52.04 8 8 52.04 8 14.91 
CXCL2 18.29 22 43.24 435.57 488.94 73.87 73.87 73.87 73.87 206.92 206.92 73.87 206.92 267.13 73.87 488.94 73.87 643.36 324.97 206.92 206.92 
CCL5 1715.6 308.1 233.5 373.7 5088.6 669.6 610.8 1090.6 481.7 801.7 733.1 669.6 458.5 1243.0 414.7 1416.8 583.1 1090.6 373.7 414.7 610.8 
Betacellulin 243.21 60 367.73 367.73 1389.62 300.63 140.65 71 71 403.86 140.65 71 140.65 37.98 140.65 71 140.65 71 300.63 216.07 300.63 
Leptin 14542 13031 13031 26861 3331 3331 3331 6661 3331 3331 35157 26861 3331 20462 35157 35157 3331 6661 20462 3331 6661 





Continued Supplemental Table 1 
dpi Mock 
Sex Male Female 
ID 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 
BAFF  615.6 615.6 615.6 767.52 812.89 748.28 748.28 748.28 748.28 715.55 665.63 715.55 615.6 532.14 880.96 748.28 615.6 615.6 
G-CSF  10 10 18.65 18.65 97.67 97.67 97.67 97.67 97.67 18.65 10 18.65 10 97.67 97.67 49 97.67 49 
GM-CSF 3.0 331.2 4.6 331.2 947.4 310.0 618.4 1922.3 618.4 4.6 331.2 4.6 331.2 618.4 1274.0 947.4 618.4 618.4 
IFN-α 33.0 1017.3 33.0 1017.3 1661.8 1661.8 74.0 1661.8 1047.5 1017.3 33.0 1017.3 1017.3 1661.8 1661.8 146.1 1047.5 146.1 
IFN-γ 6.0 6.0 6.0 38.4 34.0 67.9 67.9 34.0 67.9 11.4 38.4 11.4 11.4 67.9 34.0 67.9 34.0 67.9 
IL-1α 319.0 319.0 319.0 319.0 638.5 319.0 319.0 319.0 638.5 1411.8 1411.8 1093.5 319.0 638.5 319.0 319.0 319.0 319.0 
IL-1β 53.9 27.0 237.3 237.3 397.9 397.9 78.3 397.9 397.9 53.9 53.9 237.3 237.3 397.9 397.9 397.9 78.3 78.3 
IL-2 174.8 174.8 41.2 174.8 338.8 102.7 52.0 52.0 338.8 174.8 174.8 103.4 41.2 102.7 102.7 52.0 216.8 102.7 
IL-2R 32 62.66 62.66 62.66 124.02 124.02 63 124.02 124.02 62.66 32 62.66 32 124.02 124.02 63 124.02 63 
IL-3 24.15 24.15 88.01 24.15 189.14 10.62 110.44 110.44 110.44 24.15 88.01 24.15 24.15 10.62 110.44 10.62 67.86 110.44 
IL-4 43 43 43 160 289 289 289 289 145 43 43 160 84 289 145 289 289 289 
IL-5 237 237 237 473.2 283 565.84 283 565.84 283 237 728.11 237 237 565.84 565.84 283 283 283 
IL-6 556 1110 556 2001 3912 3912 3582 3186 3582 1110 2001 1110 556 3186 3582 3186 3186 284 
IL-7 124 247 247 2313 1162 581 581 581 581 247 247 124 2908 581 1162 581 581 1162 
IL-7Rα 342 342 342 683 365 365 365 365 728 342 342 683 342 365 365 728 728 365 
IL-10 786 786 786 786 528 528 528 528 528 786 786 786 786 528 528 528 528 528 
IL-12p70 23 23 23 23 23 23 23 25.88 13 23 23 23 23 25.88 23 23 25.88 25.88 
IL-13 21.46 21.46 66.81 112.91 84.28 84.28 3.01 84.28 195.93 21.46 112.91 209.43 11 3.01 195.93 3.01 3.01 3.01 
IL-15/IL-15R 252.85 252.85 252.85 252.85 148.12 148.12 148.12 148.12 526.37 252.85 252.85 252.85 127 148.12 148.12 75 148.12 148.12 
IL-17A  147 209 147 209 137 137 272 137 272 147 209 147 209 272 272 137 925 137 
IL-18  130 130 130 130 279 279 279 556 279 130 130 130 130 279 279 279 279 279 
IL-19 4132 4132 4132 4132 15274 15274 3286 15274 15274 8263 4132 8263 4132 15274 26619 3286 15274 26619 
IL-22  263 263 227 525 822 822 822 822 822 227 263 525 263 822 822 822 2538 822 
IL-23 323 644 323 2435 644 644 644 644 644 644 644 323 323 644 644 323 5211 5211 
IL-25 207 207 207 207 207 501 501 207 501 207 207 207 207 207 285 207 207 207 
IL-27 67 37 67 133 128 64 128 128 128 67 67 67 67 64 128 64 64 64 
IL-28 5787 13506 11573 11573 2966 13506 16256 11746 13506 11573 13506 11573 12634 16256 2966 2966 16256 13506 
IL-31 3790 3790 3790 3790 2284 2284 2284 7774 9892 3790 5205 3790 3790 8991 2284 2284 2284 8991 
IL-33 5563 5563 5563 9666 44500 44500 9867 9867 9867 5563 5563 5563 9666 44500 9867 9867 44500 4934 
IL-33R 67 1732 134 1732 2218 10568 2218 2218 4435 897 1732 134 134 2218 1822 2218 2218 4435 
LIF 21.94 21.94 21.94 11 51 51 27.64 100.1 100.1 21.94 21.94 21.94 105.66 27.64 51 51 100.1 51 
M-CSF 11 11 21.22 41.85 15 29.6 29.6 15 15 21.22 11 11 11 15 15 15 15 29.6 
RANKL 212.4 87.7 61.2 142.6 24.0 24.0 24.0 122.7 24.0 142.6 97.6 12.0 97.6 24.0 24.0 24.0 122.7 24.0 
TNFα 97 97 193.59 683.37 172.66 172.66 172.66 564.78 172.66 193.59 600.46 193.59 193.59 172.66 172.66 172.66 564.78 172.66 
CXCL5 75 763 763 1226 1005 1005 1005 503 1005 763 75 75 763 579 1005 1005 1005 1005 
CCL11 4275 713 1285 1285 1015 1015 1015 713 1015 938 1285 938 1285 1015 1015 1015 158 1015 
CXCL1 144 536 72 293 205 103 205 205 205 72 144 144 144 205 205 103 205 205 
CXCL10 1186 605 605 215 190 190 190 190 567 605 913 427 605 567 1082 190 809 190 
CCL2 523 523 523 509 990 1979 1979 990 1979 523 523 523 523 2693 1979 990 1363 1363 
CCL7 821 821 253 1154 181 181 181 181 181 821 821 253 600 181 181 181 181 181 
CCL3 46.71 56.28 37.45 37.45 320.2 287.62 287.62 287.62 334.35 20.11 20.11 37.45 28.56 287.62 267.78 287.62 347.56 287.62 
CCL4 5 8.21 23.66 37.49 158.48 35 130.05 69.45 130.05 64.55 23.66 8.21 8.21 69.45 130.05 130.05 35 69.45 
CXCL2 10 18.29 18.29 70.86 38.95 38.95 38.95 38.95 148.77 18.29 10 10 18.29 38.95 38.95 20 38.95 38.95 
CCL5 1982.0 1037.8 1167.3 1094.0 1146.8 769.1 664.2 1099.7 690.1 957.4 1037.8 615.0 1094.0 906.9 1115.3 1489.1 1068.9 921.1 
Betacellulin 59 117.44 117.44 117.44 247 247 492.35 444.81 247 243.21 243.21 117.44 117.44 444.81 492.35 247 247 247 
Leptin 3015 8452 1203 5747 2456 2456 2456 2456 2456 5747 3015 3015 5747 2456 7226 2456 2456 2456 




Supplemental Table 2. Raw cytokine concentrations in sera. 
dpi 3 7 
Sex Male Male 
ID 1 2 3 4 5 6 7 8 9 10 11 12 24 25 26 27 28 29 30 31 32 33 
BAFF  148.24 1025.37 1025.37 148.24 22 249 249 1025.37 148.24 41.77 148.24 148.24 41.77 148.24 148.24 148.24 148.24 148.24 22 1025.37 148.24 1025.37 
G-CSF  62 13.05 122.38 122.38 122.38 18.65 10 62 13.05 13.05 13.05 122.38 62 122.38 122.38 122.38 62 62 62 62 62 122.38 
GM-CSF 1667.7 47.31 47.31 47.31 47.31 331.21 4.58 47.31 24 47.31 47.31 47.31 47.31 47.31 47.31 24 47.31 24 47.31 47.31 47.31 47.31 
IFN-alpha  4406.2 4406.2 4406.2 4406.2 4406.2 33 33 4406.2 2204 4406.2 2204 4406.2 4406.2 4406.2 4406.2 5723.7 4406.2 4406.2 2204 5723.7 2204 4406.2 
IFN-gamma  9 319.14 17.07 74.2 9 38.39 38.39 319.14 9 17.07 319.14 17.07 9 9 319.14 319.14 9 17.07 9 9 17.07 319.14 
IL-1 alpha 322 643.14 322 643.14 163.77 721.98 102 322 163.77 322 322 322 322 322 643.14 322 322 322 322 322 322 322 
IL-1 beta  259 516.49 259 516.49 259 53.94 27 259 259 259 259 259 516.49 259 259 259 259 259 259 259 516.49 259 
IL-2R 16.16 16.16 16.16 114.51 192.34 62.66 32 192.34 16.16 192.34 16.16 16.16 16.16 16.16 16.16 9 16.16 16.16 192.34 9 9 9 
IL-5  262 1865.25 522.16 262 262 237 237 522.16 262 262 1865.3 262 262 262 262 262 522.16 262 262 262 262 262 
IL-6  1832 1832 3663.06 1832 1832 556 556 1832 1832 4681.6 1832 1832 4681.6 1832 1832 1832 1832 1832 1832 1832 4681.6 1832 
IL-7 553.0 1104.9 1104.9 1104.9 1104.9 246.5 124.0 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 
IL-9  286.4 286.4 286.4 286.4 286.4 286.4 286.4 286.4 286.4 286.4 286.4 286.4 144.0 286.4 144.0 286.4 144.0 144.0 286.4 144.0 144.0 144.0 
IL-10  8638.2 8638.2 8638.2 8638.2 8638.2 700.8 786.0 8638.2 8638.2 8638.2 4320.0 8638.2 8638.2 8638.2 8638.2 8638.2 8638.2 8638.2 8638.2 4320.0 4320.0 8638.2 
IL-12p70  2.14 11.23 11.23 2.14 2.14 23 23 11.23 11.23 2.14 11.23 2.14 2.14 11.23 11.23 2.14 23.97 11.23 11.23 11.23 2.14 11.23 
IL-15/IL-15R  951.73 951.73 951.73 951.73 951.73 815.39 127 951.73 951.73 476 951.73 476 951.73 951.73 951.73 951.73 476 951.73 951.73 951.73 951.73 951.73 
IL-17A  143 1155.41 1155.41 143 285.61 293.8 147 143 143 143 143 143 143 143 143 143 1155.41 143 143 143 143 143 
IL-18  1491 8250 2981 2981 2981 279 279 1491 1491 1491 2981 2981 2981 2981 2981 1491 1491 1491 1491 1491 1491 1491 
IL-19  5271 180 5271 2636 5271 4048 4132 13333 2636 5271 5271 2636 2636 5271 2636 2636 2636 2636 23339 5271 2636 23339 
IL-23 1059 1059 1059 1059 530 2672 323 1059 1059 530 530 1059 530 1059 1059 530 1059 1059 1059 1059 530 530 
IL-25  216 216 1317 216 216 413 207 216 216 216 216 216 216 861 216 216 216 216 216 431 216 216 
IL-28  86033 52261 52261 52261 52261 5787 5787 52261 52261 52261 52261 52261 52261 52261 52261 52261 26130 52261 52261 52261 52261 26130 
IL-31  9814 4907 9814 4907 9814 3790 3790 9814 9814 9814 9814 9814 9814 9814 9814 9814 9814 4907 4907 4907 9814 4907 
IL-33  44500 59654 44500 44500 44500 11125 5563 44500 44500 22250 44500 59654 22250 44500 44500 22250 22250 22250 44500 59654 44500 52890 
IL-33R  411.98 411.98 411.98 411.98 411.98 896.96 133.69 12619.57 411.98 411.98 411.98 411.98 411.98 411.98 411.98 411.98 411.98 12619.57 411.98 411.98 411.98 411.98 
M-CSF  156.43 29.39 15 15 15 11 11 15 15 15 15 15 29.39 29.39 15 15 15 15 15 15 29.39 15 
RANKL  20 20 20 20 20 3 3 20 20 20 145.42 86.91 20 4.72 20 145.42 20 86.91 20 20 20 20 
TNF alpha  335.96 335.96 335.96 335.96 168 649.97 97 335.96 335.96 335.96 168 168 168 168 168 335.96 168 335.96 335.96 168 335.96 168 
CCL11 629 629 2850 629 629 713 156 629 315 629 629 315 629 2850 2850 629 2850 629 629 629 629 629 
CXCL1 53.13 121 121 241.58 241.58 143.89 143.89 241.58 241.58 442.05 121 121 121 649.12 121 53.13 121 121 121 121 121 121 
CXCL10 1695.6 194 194 194 194 108 108 194 194 194 194 194 194 194 194 1030.44 194 194 194 194 2433.53 194 
CCL2 257.1 257.1 257.1 1736.5 257.1 1045.1 523.0 257.1 257.1 1736.5 257.1 257.1 257.1 257.1 1736.5 257.1 257.1 257.1 257.1 257.1 257.1 257.1 
CCL7 127.0 253.5 253.5 253.5 253.5 127.0 253.5 253.5 253.5 253.5 253.5 127.0 127.0 127.0 253.5 253.5 253.5 253.5 253.5 253.5 253.5 127.0 
CCL4 1.05 115.6 1.05 115.6 115.6 8.21 8.21 54.97 1.05 115.6 243.43 1.05 1.05 1.05 1.05 115.6 115.6 1.05 1.05 1.05 1.05 1.05 
CXCL2 64.19 33 33 64.19 33 10 10 33 33 33 33 33 64.19 64.19 64.19 33 33 33 33 33 64.19 33 
Leptin 54.0 54.0 54.0 54.0 54.0 1508.0 1508.0 54.0 54.0 54.0 15626.8 54.0 54.0 54.0 54.0 54.0 54.0 54.0 54.0 54.0 54.0 54.0 







Continued Supplemental Table 2 
dpi 3 7 
Sex Female Female 
ID 13 14 15 16 17 18 19 20 21 22 23 34 35 36 37 38 39 40 41 42 43 
BAFF  22 148.24 148.24 148.24 148.24 249 22 386.4 148.24 22 22 148.24 148.24 386.4 148.24 148.24 1025.37 148.24 22 41.77 22 
G-CSF  62 122.38 62 122.38 13.05 10 62 122.38 62 62 122.38 62 62 62 62 122.38 62 62 62 62 62 
GM-CSF 47.31 47.31 47.31 47.31 47.31 4.58 47.31 24 47.31 24 47.31 47.31 47.31 47.31 47.31 47.31 47.31 47.31 47.31 24 47.31 
IFN-alpha  4406.2 4406.2 4406.2 4406.2 4406.2 1017.3 2204 2204 4406.2 2204 4406.2 5723.7 2204 4406.2 5723.7 4406.2 2204 4406.2 2204 5723.7 4406.2 
IFN-gamma  17.07 319.14 17.07 17.07 9 11.44 9 9 9 9 17.07 17.07 17.07 17.07 9 74.2 9 74.2 17.07 17.07 17.07 
IL-1 alpha 643.14 643.14 322 322 322 102 2202.66 643.14 643.14 322 322 322 322 643.14 322 322 322 322 322 322 322 
IL-1 beta  259 259 259 259 259 27 259 516.49 259 259 259 259 259 516.49 259 259 259 1083.22 241.35 516.49 516.49 
IL-2R 9 192.34 16.16 16.16 114.51 62.66 192.34 114.51 9 192.34 192.34 9 9 16.16 192.34 16.16 9 16.16 114.51 16.16 16.16 
IL-5  522.16 522.16 262 262 262 237 262 262 522.16 1219.2 262 262 262 262 262 262 262 262 522.16 522.16 522.16 
IL-6  1832 1832 1832 1832 1832 556 1832 1832 1832 1832 3663.1 1832 1832 4681.6 1832 1832 1832 1832 1832 1832 1832 
IL-7 553.0 1104.9 1104.9 1104.9 1104.9 246.5 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 1104.9 553.0 1104.9 1104.9 1104.9 1104.9 1104.9 
IL-9  286.4 286.4 286.4 286.4 286.4 144.0 144.0 286.4 286.4 286.4 144.0 286.4 286.4 144.0 286.4 286.4 144.0 286.4 286.4 286.4 286.4 
IL-10  8638.2 8638.2 8638.2 8638.2 8638.2 786.0 8638.2 8638.2 8638.2 8638.2 4320.0 4320.0 8638.2 8638.2 8638.2 8638.2 8638.2 8638.2 8638.2 4320.0 8638.2 
IL-12p70  11.23 11.23 4.89 11.23 2.14 23 11.23 2.14 4.89 11.23 2.14 2.14 2.14 169.97 2.14 2.14 2.14 48.23 2.14 11.23 11.23 
IL-15/IL-15R  951.73 951.73 951.73 476 951.73 127 951.73 951.73 951.73 476 476 951.73 951.73 951.73 951.73 951.73 476 951.73 951.73 951.73 951.73 
IL-17A  143 1155.41 143 143 143 293.8 143 143 143 143 143 143 1155.41 1155.41 143 143 285.61 1155.41 285.61 143 143 
IL-18  2981 1491 2981 2981 53626 279 2981 2981 2981 1491 1491 1491 2981 2981 1491 1491 1491 2981 1491 1491 1491 
IL-19  23339 23339 5271 2636 5271 4132 23339 2636 23339 180 23339 5271 23339 13333 2636 23339 5271 23339 5271 2636 2636 
IL-23 530 1059 530 1059 530 323 1059 530 1059 530 530 530 530 1059 530 530 530 4923 530 530 1059 
IL-25  216 216 431 216 216 207 216 431 216 216 216 1317 216 216 216 216 216 216 216 216 216 
IL-28  107674 86033 26130 52261 52261 5787 52261 26130 52261 52261 52261 52261 26130 52261 52261 52261 52261 26130 52261 26130 26130 
IL-31  9814 9814 9814 9814 9814 3790 9814 9814 4907 9814 9814 9814 9814 4907 9814 4907 9814 9814 4907 9814 9814 
IL-33  22250 22250 22250 44500 44500 5563 22250 22250 52890 22250 59654 52890 22250 44500 44500 59654 44500 22250 52890 44500 22250 
IL-33R  6724.68 411.98 411.98 6724.68 411.98 133.69 411.98 411.98 411.98 411.98 411.98 411.98 411.98 12619.57 411.98 411.98 411.98 12619.57 411.98 411.98 12619.57 
M-CSF  29.39 15 29.39 15 15 11 15 15 29.39 29.39 29.39 15 15 156.43 29.39 15 15 29.39 15 156.43 15 
RANKL  38.5 145.42 20 20 145.42 3 20 20 145.42 20 20 20 20 145.42 38.5 20 145.42 4.72 20 20 20 
TNF alpha  335.96 168 168 168 335.96 193.59 335.96 168 335.96 168 168 168 335.96 168 168 168 168 335.96 168 168 168 
CCL11 2609 2850 629 629 629 1285 629 629 629 629 629 629 2850 2850 2850 3145 3145 629 629 3145 2850 
CXCL1 121 241.58 241.58 121 241.58 21.61 121 53.13 121 241.58 121 241.58 121 649.12 241.58 121 121 241.58 121 121 121 
CXCL10 194 194 194 194 194 108 194 1030.44 1030.44 194 386.82 194 194 1030.44 1030.44 194 194 1030.44 194 194 194 
CCL2 257.1 257.1 129.0 257.1 257.1 523.0 257.1 257.1 257.1 257.1 257.1 257.1 257.1 257.1 257.1 257.1 257.1 257.1 257.1 129.0 1736.5 
CCL7 253.5 253.5 253.5 127.0 253.5 253.5 127.0 127.0 253.5 253.5 253.5 253.5 253.5 253.5 253.5 253.5 253.5 127.0 127.0 253.5 253.5 
CCL4 115.6 115.6 1.05 1.05 1.05 8.21 115.6 1.05 178.69 1.05 1.05 1.05 1.05 115.6 1.05 115.6 1.05 54.97 115.6 1.05 1.05 
CXCL2 64.19 33 33 33 64.19 10 64.19 33 33 33 33 33 33 64.19 33 33 33 33 33 64.19 33 
Leptin 54.0 54.0 54.0 54.0 54.0 1508.0 54.0 107.6 3139.4 54.0 107.6 54.0 54.0 3139.4 107.6 107.6 54.0 3139.4 54.0 54.0 54.0 







Continued Supplemental Table 2 
dpi Mock 
Sex Male Female 
ID 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 
BAFF  615.6 497.42 249 497.42 135.94 68 135.94 135.94 135.94 249 249 249 249 135.94 68 135.94 135.94 135.94 
G-CSF  10 18.65 10 18.65 49 97.67 49 97.67 49 10 18.65 10 10 49 97.67 97.67 97.67 49 
GM-CSF 4.58 331.21 4.58 4.58 310 310 310 310 310 4.58 331.21 331.21 4.58 310 310 310 310 310 
IFN-alpha  509 509 509 509 74 1047.5 1661.8 1661.8 146.13 1017.3 1017.3 509 509 146.13 146.13 1661.8 146.13 146.13 
IFN-gamma  11.44 67.2 11.44 11.44 67.85 34 34 34 67.85 11.44 6 38.39 38.39 67.85 34 34 34 67.85 
IL-1 alpha 721.98 1411.8 102 102 319 319 319 319 638.47 721.98 102 102 721.98 638.47 319 319 319 319 
IL-1 beta  27 53.94 27 27 40 40 78.3 40 40 53.94 27 53.94 53.94 40 78.3 40 40 40 
IL-2R 62.66 101.63 32 62.66 124.02 63 63 63 124.02 31.71 32 32 62.66 124.02 124.02 63 124.02 63 
IL-5  237 473.2 237 237 283 283 565.84 283 283 237 295.31 237 237 283 283 283 283 283 
IL-6  556 1110.4 556 556 284.3 284.3 284.3 284.3 284.3 556 556 556 556 284.3 284.3 284.3 284.3 284.3 
IL-7 246.5 246.5 246.5 124.0 581.0 581.0 581.0 581.0 581.0 246.5 246.5 246.5 246.5 581.0 581.0 581.0 581.0 581.0 
IL-9  127.4 127.4 366.9 127.4 286.4 286.4 286.4 286.4 286.4 127.4 127.4 127.4 127.4 286.4 286.4 286.4 286.4 286.4 
IL-10  786.0 1571.2 786.0 786.0 528.1 528.1 528.1 528.1 528.1 786.0 786.0 786.0 786.0 528.1 528.1 265.0 528.1 528.1 
IL-12p70  23 45.09 23 23 13 13 13 13 13 23 23 23 23 25.88 13 13 13 13 
IL-15/IL-15R  252.85 815.39 252.85 252.85 148.12 148.12 148.12 148.12 148.12 252.85 252.85 252.85 252.85 148.12 148.12 148.12 148.12 75 
IL-17A  147 293.8 147 147 137 137 137 137 137 147 147 147 147 137 137 272.33 272.33 137 
IL-18  279 279 279 279 279 279 279 4751 279 279 279 279 279 279 279 279 279 279 
IL-19  4132 4132 4132 8263 3286 3286 15274 3286 3286 8263 4132 4132 8263 3286 3286 6571 3286 3286 
IL-23 644 2672 644 644 226 113 113 226 113 644 644 644 644 113 226 226 226 113 
IL-25  413 413 207 207 12 6 12 12 12 207 207 207 207 12 12 501 12 12 
IL-28  5787 11573 5787 5787 2966 2966 2966 2966 2966 5787 5787 5787 5787 2966 2966 2966 2966 2966 
IL-31  3790 7579 3790 3790 3790 3790 3790 3790 3790 3790 3790 3790 3790 3790 3790 3790 3790 3790 
IL-33  11125 12195 5563 5563 9867 9867 9867 9867 5563 5563 5563 5563 5563 5563 5563 5563 9867 5563 
IL-33R  133.69 2662.79 67 133.69 4435 2218 4435 2218 4435 134 134 134 134 2218 2218 2218 2218 4435 
M-CSF  11 21.22 11 11 29.6 15 15 15 15 11 11 11 21.22 15 15 15 15 15 
RANKL  3 12.03 3 12.03 24 24 24 24 24 3 3 3 3 24 24 24 24 24 
TNF alpha  97 709.7 97 97 172.66 172.66 172.66 172.66 87 97 97 193.59 193.59 172.66 87 172.66 87 87 
CCL11 938 1285 713 2850 1015 713 1015 158 713 713 820 1285 938 713 158 158 1015 713 
CXCL1 143.89 292.89 143.89 72 103 103 103 109.37 103 72 72 72 143.89 103 204.87 103 103 103 
CXCL10 108 215.15 108 108 96 96 96 65.95 65.95 108 108 108 215.15 96 96 96 96 96 
CCL2 523.0 1045.1 523.0 523.0 990.0 990.0 990.0 990.0 990.0 1045.1 523.0 508.6 523.0 990.0 990.0 990.0 990.0 990.0 
CCL7 253.5 821.4 253.5 1154.5 253.5 253.5 253.5 253.5 253.5 253.5 253.5 253.5 253.5 253.5 253.5 253.5 253.5 253.5 
CCL4 37.49 37.49 8.21 8.21 35 35 35 35 35 8.21 23.66 8.21 8.21 69.45 35 35 69.45 35 
CXCL2 10 70.86 18.29 10 20 20 20 38.95 38.95 10 10 18.29 10 38.95 38.95 38.95 20 20 
Leptin 1508.0 3015.3 1508.0 1508.0 2456.0 2456.0 2456.0 2456.0 2456.0 1508.0 1508.0 1508.0 1508.0 2456.0 2456.0 2456.0 2456.0 2456.0 







Supplemental Table 3. Raw cytokine concentrations in lungs. 
dpi 3 7 
Sex Male Male 
ID 1 2 3 4 5 6 7 8 9 10 11 12 24 25 26 27 28 29 30 31 32 33 
BAFF 352 174.2 31.85 31.85 174.2 174.2 31.85 249 715.55 615.6 715.55 497.42 352 174.2 352 31.85 31.85 174.2 174.2 174.2 174.2 174.2 
G-CSF 48 95.67 95.67 48 48 95.67 95.67 18.65 18.65 18.65 10 10 48 95.67 95.67 95.67 48 95.67 95.67 95.67 95.67 48 
GM-CSF 183.55 94 183.55 183.55 183.55 183.55 183.55 331.21 4.58 4.58 4.58 4.58 183.55 183.55 183.55 576.12 183.55 183.55 183.55 183.55 183.55 183.55 
IFN-α 144.0 144.0 1027.6 287.4 287.4 287.4 1027.6 33.0 33.0 1017.3 33.0 1017.3 1027.6 287.4 144.0 1027.6 1027.6 287.4 1027.6 287.4 1027.6 695.1 
IFN-γ 92 265 456 46 265 46 46 38 20 38 20 38 4141 4755 15211 27634 11054 3583 15211 9896 18654 9896 
IL-1α 288 288 676.58 676.58 288 288 288 288 288 288 721.98 721.98 676.58 288 676.58 825 825 288 575.08 575.08 676.58 575.08 
IL-1β 42.34 42.34 42.34 42.34 42.34 42.34 42.34 53.94 53.94 53.94 53.94 53.94 42.34 109.84 187.96 42.34 42.34 42.34 42.34 42.34 42.34 42.34 
IL-2  94 94 187.52 187.52 187.52 94 94 174.77 174.77 103.36 41.18 174.77 94 94 187.52 187.52 94 187.52 94 187.52 91.93 187.52 
IL-3  20.52 20.52 20.52 20.52 20.52 20.52 20.52 24.15 24.15 88.01 24.15 24.15 278.77 20.52 20.52 20.52 278.77 278.77 278.77 278.77 20.52 336.62 
IL-4  264.36 264.36 264.36 264.36 133 133 133 43 43 43 159.66 43 133 264.36 133 264.36 264.36 133 264.36 56.51 264.36 264.36 
IL-5  476.72 22 704.65 22 43.28 43.28 43.28 295.31 237 237 237 728.11 22 43.28 476.72 476.72 476.72 43.28 476.72 476.72 476.72 476.72 
IL-6  1529.6 2548.3 4270.7 112.1 2548.3 2548.3 112.1 556.0 1110.4 556.0 1110.4 2383.0 2548.3 2548.3 112.1 4270.7 3445.2 112.1 2548.3 112.1 4270.7 4270.7 
IL-7  1185.5 1185.5 1185.5 1185.5 1185.5 1185.5 1185.5 246.5 124.0 246.5 246.5 124.0 1185.5 1185.5 1185.5 2682.0 593.0 1185.5 593.0 1185.5 1185.5 1185.5 
IL-7Rα 2597 751 751 751 751 751 751 342 342 342 342 342 751 2597 751 2597 751 751 751 751 2597 2597 
IL-10  531 531 531 531 531 531 531 531 531 531 531 531 531 531 531 266 531 531 531 531 531 2394 
IL-12p70 30.22 30.22 30.22 30.22 16 16 16 23 23 23 23 23 30.22 30.22 136.7 30.22 30.22 30.22 30.22 30.22 16 30.22 
IL-13  30.7 30.7 30.7 30.7 30.7 131.31 30.7 21.46 21.46 21.46 21.46 21.46 30.7 30.7 30.7 16 30.7 30.7 30.7 131.31 30.7 30.7 
IL-15  101 200.69 200.69 200.69 200.69 200.69 200.69 252.85 252.85 252.85 252.85 127 512.64 200.69 200.69 512.64 512.64 200.69 512.64 200.69 704.54 512.64 
IL-17A  575.0 1149.7 575.0 1149.7 575.0 575.0 1149.7 147.0 293.8 147.0 147.0 293.8 1149.7 1149.7 575.0 575.0 575.0 1149.7 575.0 1149.7 1149.7 1149.7 
IL-18  153.0 305.9 305.9 305.9 305.9 305.9 305.9 130.0 130.0 130.0 130.0 130.0 153.0 153.0 305.9 153.0 305.9 305.9 1374.9 305.9 305.9 305.9 
IL-22  377 377 377 377 377 189 377 263 263 263 263 227 377 377 1013 697 377 377 377 377 1678 377 
IL-23  595.5 595.5 595.5 298.0 595.5 595.5 595.5 323.0 644.2 644.2 644.2 644.2 595.5 595.5 595.5 7647.0 6627.6 595.5 595.5 595.5 595.5 595.5 
IL-25 405.89 101 405.89 405.89 101 200.34 405.89 207 207 207 207 207 200.34 405.89 405.89 101 101 101 405.89 200.34 101 405.89 
IL-27  30.58 110.35 56 56 56 247.82 56 67 67 67 36.6 369.93 56 56 56 56 110.35 247.82 110.35 448.1 110.35 56 
IL-28  68 4575 11130 68 68 68 4575 5787 5787 13506 11573 11573 21752 4575 11130 68 4575 68 68 1202 68 4575 
IL-33  11681 11681 24685 17810 11681 24685 11681 5563 13114 11125 5563 12195 43999 24685 24685 24685 24685 24685 24685 24685 11681 43999 
IL-33R  278.8 6125.4 278.8 278.8 278.8 278.8 278.8 133.7 3690.0 2662.8 133.7 133.7 278.8 278.8 278.8 278.8 278.8 278.8 278.8 278.8 278.8 278.8 
LIF  131.37 11.13 11.13 11.13 11.13 131.37 131.37 21.94 105.66 21.94 105.66 21.94 11.13 66.56 6 131.37 293.58 6 131.37 293.58 131.37 66.56 
M-CSF 13.39 1.95 1.95 1.95 1.95 13.39 13.39 11 11 21.22 21.22 11 13.39 1.95 6.61 1 13.39 6.61 13.39 1 6.61 1.95 
RANKL  28.56 28.56 28.56 10.78 28.56 28.56 28.56 12.03 142.6 32.85 87.69 32.85 28.56 54.7 28.56 89.28 54.7 28.56 89.28 28.56 28.56 54.7 
TNFα 197.37 197.37 197.37 197.37 99 197.37 197.37 193.59 193.59 97 193.59 193.59 197.37 197.37 197.37 197.37 400.69 99 197.37 197.37 400.69 197.37 
CXCL5 250.0 1300.7 1300.7 250.0 498.3 1300.7 1300.7 75.0 762.6 762.6 75.0 762.6 1300.7 250.0 1300.7 2274.9 1300.7 250.0 1300.7 1300.7 1300.7 1300.7 
CCL11 4275 2850 4275 2850 2850 4275 4275 4275 4275 4275 4275 4275 2850 2850 2850 4275 4275 4275 4275 2850 4275 2850 
CXCL1 1347.3 356.0 573.9 126.3 800.4 126.3 126.3 292.9 1297.2 501.0 292.9 362.3 356.0 356.0 356.0 64.0 356.0 356.0 356.0 356.0 244.7 356.0 
CCL2 536 268 1496 268 536 268 268 523 523 523 523 2674 536 1496 1496 3044 2517 268 2517 1496 4666 2517 
CCL7 1208.0 501.0 972.2 30.8 736.5 30.8 30.8 1154.5 2931.9 2034.3 3120.7 3300.1 736.5 501.0 972.2 972.2 736.5 854.4 972.2 972.2 972.2 972.2 
CCL3 85.23 53.28 85.23 23.68 23.68 38.52 15.56 5.13 28.56 20.11 118.78 260.92 122.68 168.13 317.76 144.23 133.19 68.72 296.64 168.13 296.64 168.13 
CCL4 100.68 67.19 67.19 34 100.68 67.19 34 8.21 37.49 8.21 37.49 120.63 124.83 124.83 156.46 187.11 166.63 100.68 230.88 187.11 208.32 208.32 
CXCL2 43.24 22 43.24 22 43.24 22 43.24 18.29 18.29 18.29 10 18.29 43.24 43.24 43.24 43.24 43.24 22 43.24 22 22 43.24 
CCL5 441.2 265.2 286.6 340.8 407.4 308.1 286.6 314.4 615.0 412.5 1342.1 1010.5 202.3 340.8 385.0 141.8 233.5 319.0 396.2 244.0 297.3 223.1 
BTC 118.67 118.67 118.67 60 118.67 118.67 60 117.44 117.44 117.44 117.44 243.21 60 60 118.67 118.67 118.67 60 118.67 118.67 118.67 118.67 






Continued Supplemental Table 3 
dpi 3 7 
Sex Female Female 
ID 13 14 15 16 17 18 19 20 21 22 23 34 35 36 37 38 39 40 41 42 43 
BAFF 31.85 16 31.85 31.85 31.85 352 4791.49 2462.5 497.42 497.42 344.29 174.2 31.85 31.85 31.85 31.85 31.85 31.85 31.85 174.2 31.85 
G-CSF 95.67 95.67 48 48 48 95.67 92.41 47 18.65 18.65 18.65 95.67 95.67 95.67 48 95.67 95.67 95.67 48 95.67 48 
GM-CSF 183.55 183.55 183.55 183.55 183.55 183.55 135 927.18 4.58 158.1 4.58 183.55 183.55 183.55 183.55 183.55 183.55 183.55 183.55 183.55 183.55 
IFN-alpha 1027.6 1027.6 1027.6 287.4 695.1 695.1 920.0 1838.6 1017.3 33.0 33.0 144.0 1027.6 287.4 144.0 287.4 144.0 287.4 287.4 144.0 1027.6 
IFN-gamma 265 46 265 265 46 46 104 104 20 20 38 1183 2616 670 2616 265 4755 6168 1183 1825 1183 
IL-1 alpha  288 288 288 288 676.58 825 1677.15 1677.15 721.98 288 721.98 676.58 676.58 288 676.58 288 288 288 288 676.58 288 
IL-1 beta  42.34 42.34 42.34 42.34 42.34 42.34 224.7 224.7 237.3 53.94 53.94 42.34 42.34 42.34 42.34 42.34 42.34 187.96 42.34 42.34 42.34 
IL-2  94 94 187.52 94 187.52 94 225.41 113 174.77 174.77 41.18 187.52 187.52 94 94 187.52 187.52 187.52 187.52 187.52 94 
IL-3  20.52 278.77 20.52 20.52 278.77 20.52 2.43 2.43 88.01 24.15 24.15 20.52 20.52 278.77 20.52 20.52 20.52 20.52 20.52 20.52 20.52 
IL-4  264.36 133 133 264.36 56.51 264.36 1089.99 54 43 159.66 43 264.36 133 264.36 133 56.51 264.36 264.36 264.36 133 133 
IL-5  22 43.28 476.72 22 43.28 43.28 800.98 44.56 237 237 237 476.72 43.28 43.28 43.28 254.47 476.72 43.28 43.28 476.72 22 
IL-6  2548.3 2548.3 2548.3 112.1 112.1 112.1 4278.6 4278.6 1110.4 556.0 556.0 1529.6 112.1 112.1 2548.3 1529.6 2548.3 112.1 112.1 57.0 112.1 
IL-7  1185.5 1185.5 1185.5 1185.5 1185.5 1185.5 254.7 254.7 2313.1 246.5 124.0 1185.5 1185.5 1185.5 1185.5 593.0 1185.5 1185.5 1185.5 1185.5 1185.5 
IL-7R alpha 751 751 751 751 751 751 3325 3325 342 342 342 751 751 2597 751 751 2597 751 751 751 751 
IL-10  531 531 266 531 531 531 1077 2152 531 531 531 266 531 531 531 531 531 531 531 531 531 
IL-12p70 30.22 16 30.22 136.7 16 30.22 102.41 60 23 23 23 16 30.22 30.22 30.22 30.22 30.22 30.22 30.22 30.22 30.22 
IL-13  16 30.7 30.7 30.7 30.7 16 124 124 21.46 21.46 21.46 30.7 16 30.7 30.7 30.7 30.7 30.7 30.7 131.31 30.7 
IL-15/IL-15R  200.69 200.69 200.69 200.69 200.69 200.69 148.4 148.4 252.85 252.85 252.85 200.69 200.69 200.69 200.69 200.69 704.54 200.69 200.69 200.69 200.69 
IL-17A  575.0 575.0 575.0 575.0 575.0 1149.7 478.5 478.5 147.0 147.0 147.0 575.0 1149.7 575.0 575.0 575.0 1149.7 1149.7 575.0 575.0 575.0 
IL-18  305.9 153.0 153.0 305.9 153.0 305.9 130.0 165.4 130.0 130.0 130.0 153.0 305.9 305.9 305.9 305.9 1374.9 305.9 305.9 153.0 305.9 
IL-22  377 377 377 377 377 377 207 414 525 263 263 377 377 377 377 189 377 1013 1013 377 1013 
IL-23  595.5 595.5 595.5 595.5 595.5 6627.6 1143.6 4873.8 644.2 644.2 644.2 595.5 6627.6 298.0 595.5 595.5 6627.6 6627.6 595.5 595.5 298.0 
IL-25 405.89 101 566.98 101 200.34 101 359.31 359.31 207 412.75 207 101 101 405.89 405.89 101 101 405.89 101 200.34 101 
IL-27  56 56 56 56 56 56 698.23 134.8 133.11 67 133.11 56 247.82 110.35 56 56 56 56 56 110.35 56 
IL-28  68 68 35 68 68 68 89993 54025 11573 11573 5787 68 68 68 68 68 68 68 68 4575 68 
IL-33  11681 11681 11681 24685 24685 11681 5563 9755 11125 11125 5563 11681 24685 24685 17810 24685 24685 17810 24685 11681 11681 
IL-33R  278.8 278.8 278.8 278.8 278.8 278.8 3063.0 3063.0 1732.4 133.7 133.7 278.8 278.8 6125.4 278.8 278.8 278.8 278.8 278.8 278.8 278.8 
LIF  11.13 131.37 6 131.37 6 66.56 52 102.66 105.66 21.94 21.94 131.37 131.37 131.37 6 131.37 11.13 131.37 131.37 131.37 66.56 
M-CSF 1.95 6.61 1 1 1 13.39 91.48 46 11 11 11 1.95 1.95 1 1 1.95 1.95 1.95 1 1.95 13.39 
RANKL  28.56 28.56 10.78 10.78 10.78 10.78 17 17 78.34 118.95 21.52 1.98 10.78 10.78 28.56 28.56 28.56 54.7 28.56 28.56 54.7 
TNF alpha  197.37 197.37 197.37 197.37 197.37 197.37 166.73 166.73 193.59 193.59 193.59 197.37 197.37 99 197.37 197.37 197.37 197.37 99 99 197.37 
CXCL5 250.0 1300.7 250.0 250.0 1300.7 250.0 2755.8 2755.8 75.0 75.0 762.6 498.3 1300.7 1300.7 250.0 1300.7 1300.7 1300.7 1300.7 1300.7 1300.7 
CCL11 4275 2850 858 2850 2850 2850 4275 4275 2850 4275 4275 2850 2850 2850 2850 713 2850 2850 2850 2850 2850 
CXCL1 126.3 64.0 126.3 126.3 356.0 64.0 142.7 142.7 21.6 143.9 143.9 126.3 126.3 126.3 356.0 64.0 126.3 356.0 126.3 126.3 356.0 
CCL2 268 268 268 268 268 268 288 574 1045 523 523 268 268 104 268 268 1496 104 268 268 536 
CCL7 30.8 30.8 30.8 30.8 501.0 30.8 825.0 1048.6 1154.5 821.4 821.4 30.8 501.0 501.0 265.7 501.0 501.0 736.5 501.0 501.0 736.5 
CCL3 4.43 4.43 4.43 4.43 23.68 4.43 27.08 93.75 37.45 37.45 5.13 23.68 38.52 68.72 38.52 38.52 133.19 168.13 103.12 53.28 85.23 
CCL4 34 34 34 34 34 34 8 14.91 8.21 8.21 37.49 34 34 34 34 67.19 146.19 187.11 67.19 100.68 100.68 
CXCL2 22 22 43.24 43.24 22 22 206.92 206.92 18.29 18.29 10 22 43.24 22 22 43.24 43.24 43.24 43.24 43.24 22 
CCL5 407.4 407.4 286.6 141.8 362.9 286.6 436.2 414.7 970.5 655.7 957.4 244.0 181.9 202.3 254.6 265.2 265.2 319.0 351.8 373.9 396.2 
Betacellulin 118.67 118.67 60 118.67 118.67 60 140.65 71 185.23 117.44 59 197.31 118.67 118.67 60 118.67 197.31 118.67 118.67 60 118.67 






Continued Supplemental Table 3 
dpi Mock 
Sex Male Female 
ID 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 
BAFF 249 497.42 249 715.55 135.94 135.94 135.94 748.28 68 249 497.42 249 497.42 135.94 68 135.94 135.94 135.94 
G-CSF 10 10 18.65 108.99 49 97.67 97.67 97.67 97.67 10 18.65 10 18.65 49 97.67 97.67 49 49 
GM-CSF 3 4.58 4.58 513.51 310 310 310 310 310 4.58 3 4.58 4.58 310 310 310 310 310 
IFN-alpha 33.0 33.0 1017.3 1956.5 146.1 146.1 1661.8 74.0 74.0 33.0 1017.3 1017.3 33.0 74.0 74.0 146.1 74.0 1661.8 
IFN-gamma 20 25 20 67 34 34 34 34 34 20 20 20 20 34 34 34 34 34 
IL-1 alpha  721.98 288 288 1411.8 288 288 288 288 288 288 288 288 288 288 288 288 288 288 
IL-1 beta  27 27 27 237.3 397.87 78.3 78.3 40 40 27 27 53.94 27 40 397.87 40 40 40 
IL-2  21 41.18 21 336.14 102.67 102.67 52 102.67 52 41.18 41.18 41.18 41.18 52 102.67 102.67 52 102.67 
IL-3  24.15 24.15 24.15 101.04 10.62 10.62 10.62 10.62 10.62 24.15 24.15 24.15 24.15 10.62 10.62 10.62 10.62 10.62 
IL-4  43 43 43 159.66 145 289.3 145 289.3 145 43 159.66 159.66 43 145 289.3 289.3 145 145 
IL-5  237 237 237 728.11 283 283 283 283 283 237 237 237 237 283 283 283 283 283 
IL-6  556.0 1110.4 556.0 2001.4 284.3 284.3 284.3 284.3 284.3 556.0 556.0 556.0 556.0 284.3 284.3 284.3 284.3 3186.1 
IL-7  246.5 246.5 124.0 2908.4 581.0 581.0 581.0 581.0 581.0 246.5 124.0 246.5 246.5 581.0 581.0 581.0 581.0 581.0 
IL-7R alpha 342 342 342 4163 365 365 365 365 365 342 342 342 342 365 365 365 365 365 
IL-10  531 531 531 2360 528 528 528 528 528 531 531 531 531 528 528 528 528 528 
IL-12p70 23 23 23 104.24 23 23 23 23 23 23 23 23 23 23 23 23 23 23 
IL-13  21.46 21.46 21.46 209.43 2 3.01 3.01 2 3.01 21.46 11 21.46 21.46 2 2 3.01 3.01 3.01 
IL-15/IL-15R  252.85 252.85 252.85 917.06 148.12 148.12 75 148.12 148.12 252.85 252.85 252.85 252.85 148.12 148.12 148.12 148.12 75 
IL-17A  209.4 293.8 147.0 414.6 137.0 137.0 137.0 137.0 137.0 147.0 293.8 147.0 147.0 137.0 137.0 137.0 137.0 137.0 
IL-18  130.0 130.0 130.0 130.0 279.0 279.0 279.0 279.0 279.0 130.0 130.0 130.0 130.0 279.0 279.0 279.0 279.0 279.0 
IL-22  263 263 263 1076 822 822 822 822 822 263 263 263 263 822 822 822 822 822 
IL-23  644.2 644.2 644.2 2962.5 226.0 226.0 226.0 226.0 226.0 644.2 644.2 2672.1 644.2 226.0 226.0 226.0 226.0 226.0 
IL-25 207 207 412.75 677.91 207 207 207 207 207 207 207 412.75 207 501.4 207 207 501.4 501.4 
IL-27  67 67 67 640.84 64 127.6 64 64 64 67 67 67 67 64 64 64 64 64 
IL-28  5787 5787 11573 11573 2966 2966 2966 2966 2966 5787 5787 11573 5787 2966 2966 2966 2966 2966 
IL-33  5563 11125 11125 13114 9867 44500 9867 9867 9867 5563 5563 5563 5563 9867 9867 9867 4934 37246 
IL-33R  133.7 133.7 133.7 3690.0 2218.0 2218.0 2218.0 2218.0 2218.0 133.7 133.7 1732.4 133.7 2218.0 2218.0 1821.5 2218.0 2218.0 
LIF  105.66 60.19 21.94 331.8 51 51 51 51 51 60.19 105.66 21.94 21.94 51 100.1 100.1 51 51 
M-CSF 11 11 11 41.85 15 15 15 29.6 15 11 11 11 11 15 15 29.6 29.6 29.6 
RANKL  46.06 46.06 32.85 97.56 24 24 24 24 24 32.85 46.06 46.06 142.6 24 24 24 24 24 
TNF alpha  193.59 193.59 193.59 709.7 172.66 87 172.66 172.66 87 193.59 193.59 193.59 193.59 172.66 87 87 172.66 172.66 
CXCL5 75.0 762.6 762.6 2011.8 578.8 1005.1 578.8 503.0 503.0 762.6 762.6 75.0 75.0 503.0 503.0 503.0 503.0 1005.1 
CCL11 2850 2850 2850 4275 2850 2850 2850 2850 713 4275 938 4275 938 2850 1015 2850 4275 4275 
CXCL1 72.0 643.8 143.9 431.4 103.0 103.0 204.9 381.4 103.0 72.0 72.0 98.0 72.0 103.0 103.0 103.0 103.0 204.9 
CCL2 523 523 523 1918 990 990 990 990 990 523 523 1045 1045 990 990 990 1979 990 
CCL7 253.5 253.5 821.4 1292.7 180.8 180.8 180.8 180.8 91.0 253.5 253.5 253.5 253.5 180.8 91.0 180.8 180.8 180.8 
CCL3 5.13 5.13 5.13 28.56 243.4 29.45 29.45 29.45 15 20.11 20.11 5.13 20.11 29.45 15 29.45 29.45 29.45 
CCL4 5 8.21 8.21 64.55 35 35 35 35 35 37.49 8.21 8.21 8.21 35 35 31.94 35 35 
CXCL2 10 18.29 18.29 70.86 20 38.95 38.95 38.95 20 18.29 10 10 10 38.95 20 20 20 38.95 
CCL5 267.7 354.5 191.7 191.7 465.0 160.0 513.9 416.4 128.4 267.7 412.5 429.6 412.5 651.4 343.3 465.0 538.5 588.2 
Betacellulin 243.21 59 117.44 349.72 59 59 59 59 59 59 117.44 59 117.44 59 59 59 59 59 










Johns Hopkins University, Bloomberg School of Public Health                                Sep. 2019-Present 
• Sc.M. in Biochemistry and Molecular Biology 
Shanghai Jiao Tong University, School of Medicine                                                Sep. 2015-Jun. 2019 
• B.S. in Medical Laboratory Tech 
ACADEMIC EXPERIENCES 
Research Experiences: 
Sex Differences in the Influenza B Virus (IBV) Pathogenesis                                         Jun. 2020-Present 
Johns Hopkins University, Bloomberg School of Public Health  
Advisor: Dr. Sabra Klein, Professor  
Contribution: 
• Established mouse model of IBV, including conducting mLD50 tests, using morbidity and mortality 
• Mastery of infection protocols for both mice (in vivo) and cell culture (in vitro), with analysis of virus 
titration and quantification in tissues and cells and optimization of protocols specific for IBV 
• Mastery of animal handling, dissection, and tissue and blood collection techniques  
• Utilization of basic microbiological and immunological assays including TCID50, ELISA, 
microneutralization, and cytokine multiplex assays  
Correlation Analysis of Vaginal Microbiome Diversity and Cervical Intraepithelial Neoplasia 
Obstetrics and Gynecology Hospital of Fudan University, Clinical Lab                         Oct. 2018-Apr. 2019 
Advisor: Dr. Chunmei Ying, Chair 
Contribution: 
• Collected and stored clinical vaginal swab specimens 
• Analyzed the diversity data of vaginal microbiome from 32 cases; compared alpha and beta diversity 
between different levels of cervical intraepithelial neoplasia 
Method Development for the Detection of a MyD88 Point Mutation using allele specific-PCR 
Shanghai Ruijin Hospital                                                                                                Jun. 2017-Jul. 2017 
Advisor: Dr. Lei Dong, Associate Chief Physician 
Contribution: 
• Retrieved genetic databases for the sequence of a specific Myd88 point mutation; designed TaqMan 
probes, quality control plasmids, and six PCR primer pairs in Amplification Refractory Mutation 
System (ARMS) method for the detection of Myd88 point mutation 
• Performed qRT-PCR to detect diluted plasmids; verified the eligibility of each primer pair  
• Determined the optimal initial concentration of ARMS primer pair 
 
 60 
Microfluidic Chip Design for Early Detection of Breast Cancer in Digital PCR Method       
Shanghai Jiao Tong University School of Biomedical Engineering           May 2017-Dec. 2018 
Advisor: Dr. Xianting Ding, Professor 
Contribution: 
• Wrote research proposal, mainly tasked with the study design 
• Compared several detection methodologies and suggested to combine microdroplet chip with digital 
PCR 
• Improved the existing chip design and drew the sketch for chip fabrication 
• Finished two literature reviews 
Conference Presentations:  
• Woldetsadik Y, Wang A, Perez D, Cardenas-Garcia S, Klein SL. Characterizing sex differences in 
Influenza B virus pathogenesis in C57BL/6 mice. Centers of Excellence for Influenza Research and 
Surveillance (CEIRS) (2021) *Poster awarded* 
• Wang A, Cardenas-Garcia S, Rajao D, Perez D Klein SL. The effect of biological sex on influenza B 
virus pathogenesis in C57BL/6 mice. American Society for Virology (2021) *Poster Presentation* 
Peer Reviewed Publications: 
• Wang A, Abdulla A, Ding X. Microdroplets-on-chip: A review. Proceedings of the Institution of 
Mechanical Engineers, Part H: Journal of Engineering in Medicine. 2019;233(7):683-694. 
doi:10.1177/0954411919850912 
Ad hoc peer review: 
• Journal of Virology: Defective NKp46 recognition and elimination of influenza B viruses (2020) 
• EBioMedicine: Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 
disease in males (2020) 
• Scientific Report: Male to female ratio of influenza morbidity switches between children and adults 
(2020) 
INTERNSHIPS 
Roche Diagnostics, Shanghai                                                                                      Nov. 2018-Jun. 2019 
Assistant to Bidding Operation Team 
• Established and optimized the database of 200 products 
• Assisted with the confirmation of actions for identified tenders in the first and second quarter of 2019, 
followed up bidding results, and conducted bidding data analysis  
Obstetrics and Gynecology Hospital of Fudan University                                      May 2018-Nov. 2018 
Intern in Clinical Lab 
• Outpatient Care: took charge of finger blood routine and urine routine examinations 
• Blood Specimen Lab: collected and pre-processed the clinical specimens; read blood smears; used 
automatic instruments to perform immunological and biochemical examination, issued test reports and 
provided consultations for physicians; performed quality control and maintenance for instruments 
• Microbe Lab: took charge of specimen inoculation and chlamydia examination  
Shanghai Ruijin Hospital                                                                                             Jul. 2017-Aug. 2017 
Intern in Clinical Lab 
• Responsible for specimen collection and pretreatment, finger blood collection 




• Blood smear staining and morphology examination 
• Bacteria and cell cultivation; virus propagation and titration 
• Animal modeling and surgery 
• Neutralizing assay, ELISA 
Software 
• Stata 15, R, Primer 5, Prism, Microsoft Office 
